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Adrenal corticosteroids play a major role in the negative feedback control of the
hypothalamic-pituitary-adrenal axis, which ensures that corticosteroid levels are
optimal for homeostatic adaptation. The objective of this thesis was to
investigate the mechanism of the action of glucocorticoids on stimulus evoked
adrenocorticotrophic hormone (ACTH) secretion by anterior pituitary cells in
vitro. Primary cultures of rat anterior pituitary cells and the mouse corticotroph
tumour cell line AtT20 were used.
Early glucocorticoid inhibition was found to require the synthesis of new mRNA
and proteins. Previous work indicated that calmodulin is one of the
glucocorticoid-induced proteins that may mediate the inhibitory action of
glucocorticoid on ACTH secretion. Therefore, AtT20 cells that constitutively
over-expressed chicken calmodulin were established to test if elevated
calmodulin level could mimic glucocorticoid action. Corticotrophin releasing
factor (CRF)-stimulated ACTH secretion by stably transfected AtT20 cells that
showed elevated calmodulin mRNA and protein levels and wild type AtT20 cells
was found not to be significantly different. Events downstream to the de novo
synthesis of proteins in glucocorticoid feedback inhibition were studied in
cultured rat anterior pituitary cells. Membrane depolarization elicited by a
combination of a depolarizing concentration of KC1 with 8-(4-chlorophenylthio)
adenosine-3',5'-cyclic-monophosphate (CPT-cAMP) or CRF antagonized the
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glucocorticoid inhibition of stimulated ACTH secretion. Since the control of
membrane potential involves K+-channels, the effect of K+-channel blockers on
glucocorticoid inhibition was tested. The BK-channel inhibitor, charybdotoxin,
had no significant effect on glucocorticoid inhibition, nor did other common K+-
channel blockers (tetraethylammonium, apamin and 4-aminopyridine). Clofilium
(IsK-type K+-channel blocker) and astemizole (an antihistamine with anti-
HERG-type K+-channel properties) were found to significantly reduce the
inhibition of the CRF response by glucocorticoid. More specific blockers of IsK-
type K+-channels (chromanol 293B, WAY-123398) or HERG-type K+-channels
(E4031, dofetilide) had no significant effect on glucocorticoid inhibition.
Previous studies have also suggested that control of intracellular cAMP levels via
Ca2+-dependent feedback is important in glucocorticoid inhibition. Hence, it was
tested if clamping of cAMP at high levels could alter glucocorticoid inhibition.
High cAMP levels were induced and sustained using arginine vasopressin (AVP)
or rolipram (inhibitor of cAMP-dependent cyclic nucleotide phosphodiesterase)
in combination with CRF. The glucocorticoid inhibition of ACTH response
elicited by CRF/AVP or CRF/rolipram was markedly attenuated. Since protein
phosphorylation is integral to cAMP accumulation and cAMP-activated
responses, the effect of FK506 (a potent inhibitor of protein phosphatase 2B,
calcineurin) was also investigated. In combination with CRF, FK506 elicited an
ACTH response that was less effectively inhibited by glucocorticoid.
To summarize, the role of calmodulin as a mediator of glucocorticoid feedback
inhibition could not be confirmed in cells AtT20 cells constitutively over-expressing
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calmodulin. The data do support the thesis that feedback inhibition by
glucocorticoid targets the membrane potential. Furthermore, plasma membrane K+-
channels appear to be involved in glucocorticoid action. However, it was not
possible to identify these channels by means of currently available pharmacological
agents. The results also show that intracellular cAMP levels modulate the efficiency
of glucocorticoid inhibition in normal rat corticotrophs and support the notion that
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1.1.1 Stress and the Hypothalamic-Pituitary-Adrenal axis
A challenge to adaptation from the environment (stressor) activates pleiotropic
homeostatic control mechanisms including the immune, central nervous and
metabolic control systems, collectively geared towards the restoration of the
homeostatic balance of the organism. However, if left unchecked, these powerful
stress-induced defence reflexes can overshoot and lead to a collapse of body
homeostasis. Consequently, a key function of adrenal corticosteroids (primarily
glucocorticoids) released during stress is to terminate these stress-mobilised
compensatory defence responses , thereby preventing maladaptation to stress.
The secretion of adrenal glucocorticoids into the peripheral circulation in response to
stress is regulated through a classical neuroendocrine negative feedback loop, the
hypothalamic-pituitary-adrenal (HPA) axis (Figure 1.1). The physiological role of
the HPA axis is to tightly regulate plasma glucocorticoid levels in order to maintain
cellular homeostasis in response to changes in the environment [see (Dallman et al.,
1987; Jones & Gillham, 1988; Keller-Wood & Dallman, 1984) for reviews]. Stress
activates the HPA axis, resulting in the release of the major hypothalamic












Figure 1.1: 41-residue corticotrophin-releasing factor (CRF) and arginine
vasopressin (AVP) are the major hypothalamic secretagogues of
adrenocorticotrophic hormone (ACTH) from the anterior lobe of the pituitary gland.
ACTH in turns stimulates the secretion of glucocorticoids (mainly Cortisol in humans
and corticosterone in rats) from the cortex of the adrenal gland. Glucocorticoids
limit their own production through negative feedback inhibition at the pituitary, the




vasopressin (AVP) into the hypothalamo-hypophysial portal circulation that
stimulate the secretion of ACTH from anterior pituitary corticotrophs. (Figure 1.1).
Anatomical studies suggest CRF and AVP are produced in the paraventricular
nucleus in the hypothalamus via 3 ways (Antoni, 1986; Antoni, 1993; Plotsky,
1988). The parvocellular neurons (which project into the median eminence) are
divided into 2 kinds, one expressing CRF exclusively while the other expressing both
CRF and AVP. The magnocellular neurons (which project into the posterior
pituitary lobe) produce only AVP and may release it into the portal vessels in the
median eminence en passant. The subsequent ACTH secretion in turn stimulates the
release of glucocorticoids (principally Cortisol in man, and corticosterone in rats)
from the adrenal glands, which affects a wide range of physiological control systems
including carbohydrate metabolism, body fluid balance, neural activity as well as
anti-inflammatory and immunosuppressive actions (Munck et al., 1984; Munck et
ah, 1990). Besides counteracting stress-induced homeostatic defence mechanisms,
glucocorticoids also limit their own production through feedback inhibition of the
HPA axis activity at several major feedback sites, including the anterior pituitary
gland, the hypothalamus and further sites in the central nervous system (Sapolsky et
al., 1990). Additionally, physiologically relevant hypothalamic inhibitors of ACTH
release such as atrial natriuretic peptide may provide further inhibitory control of the




1.1.2 Glucocorticoid feedback inhibition
The regulation of plasma corticosteroid levels is vital since prolonged exposure to
glucocorticoids will lead to over-suppression of the stress-activated compensatory
responses, which may thwart the maintenance of homeostasis.
Glucocorticoids exert their effects in at least two phases: early (occurring within
minutes to ~3 h after glucocorticoid exposure) and late (requiring >6 h to days)
(Shipston, 1992). The early phase of glucocorticoid inhibition can be further divided
into fast effects (taking place in a matter of seconds to a few minutes) and delayed
actions that require several minutes up to 2 h after glucocorticoid administration).
Early fast inhibition does not require the interaction of steroid receptors with
regulatory sequences in DNA while early delayed action generally involves the
induction of new mRNA and protein. Examples of early inhibition include inhibition
of ACTH release from anterior pituitary corticotrophs cf (Keller-Wood & Dallman,
1984), inhibition of interleukin 1 (IL-1) (Snyder & Unanue, 1982) and IL-2 (Gillis et
al., 1979; Gillis et al., 1979) secretion by cells of the immune system (macrophages
and T cells respectively) and also suppression of glucose transport in lymphocytes
(Munck et al., 1978). Late inhibition generally involves down-regulation of gene-
transcription as well as suppression of differentiated cellular functions, for example
suppression of proopiomelanocortin (POMC) synthesis in anterior pituitary
corticotrophs or induction of apoptosis in lymphocytes (Jones & Gillham, 1988;
Keller-Wood & Dallman, 1984; Munck et al., 1984). A recent study showed that in
cultures of rat anterior pituitary cells, glucocorticoids can downregulate the mRNA
4
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levels of the CRF type I receptor (in the time frame of late inhibition) (Pozzoli et al.,
1996).
In sum, with respect to glucocorticoid feedback inhibition of the anterior pituitary
corticotroph, it is well-characterised that late glucocorticoid inhibition results in the
depletion of intracellular ACTH stores and downregulation of signalling pathways
[see (Dallman et al., 1987; Johnson et al., 1982; Jones & Gillham, 1988; Keller-
Wood & Dallman, 1984; Lundblad & Roberts, 1988; McEwen, 1991) for reviews].
In contrast, early glucocorticoid action results in the inhibition of stimulated ACTH
secretion through a mechanism that is not well understood other than that it is
mediated by newly induced proteins [(Portanova & Sayers, 1974; Shipston &
Antoni, 1992; Taylor et al., 1993) and see section 1.3.1].
1.1.3 Why study the mechanism(s) ofglucocorticoid feedback inhibition?
Glucocorticoids are the key stress hormones responsible for preventing the escalation
of the defence mechanisms mobilised during stress. However, excessively high
levels of glucocorticoids can have undesirable effects. This may be the reason for
the diurnal fluctuations of free Cortisol in humans (Baxter & Tyrrell, 1987) and
corticosterone in rats (Jacobson et al., 1988) since hormone levels beneficial in the
short run may become harmful in the long run. Thus, glucocorticoid-mediated
feedback inhibition (which limits its own amounts in circulation) is the physiological
process that serves this purpose.
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High glucocorticoid levels may over-suppress the production of cytokines for
instance (due to the anti-inflammatory and immunosuppressive actions of
glucocorticoids (Munck & Guyre, 1991; Munck et al., 1984; Munck et al., 1990)),
resulting in the impairment of the immune system. Glucocorticoid excess can also
increase the likelihood of diseases like diabetes, hypertension, impotency and
myopathy. Furthermore, Cushing's disease and psychiatric disorders like major
depression and posttraumatic stress disorder are exemplified by a dysfunctional HPA
axis. Cushing's disease is primarily caused by a pituitary tumour (which may or may
not hypersecrete ACTH) and is characterised by a disturbance in the corticosteroid
feedback mechanism (Burch, 1985). Cushing's syndrome, on the other hand, can be
broadly classified as being caused by various kinds of tumours (usually an ectopic
ACTH-producing tumour or adrenal cortical tumour) that directly or indirectly
results in the hypersecretion of glucocorticoids (Newell-Price et al., 1998). Major
depression is characterised biologically by a dysfunctional HPA axis (which can be
induced by chronic corticosteroid exposure or stress alone) leading to
hypercortisolaemia (Carroll et al., 1981; Sapolsky et al., 1986; Young et al., 1991).
Neuroendocrine studies examining the HPA axis under baseline conditions and in
response to neuroendocrine challenges have similarly proposed an altered HPA
functioning in posttraumatic stress disorder (Yehuda et al., 1991), resulting in
Cortisol hypersecretion during the period of traumatic stress (Sapolsky, 1997). Thus,
better understanding of the mechanisms of glucocorticoid negative feedback
inhibition would greatly contribute to any potential development of therapeutic
strategies for these diseases.
6
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The murine corticotroph tumour cell line AtT20 is used as a model system for the
study of early glucocorticoid feedback inhibition in adenophypophysial
corticotrophs. Both cell types are electrically active and their functions are closely
coupled to ion channel activity regulated by membrane voltage (Adler et al., 1983;
Reisine, 1989; Suprenant, 1982; Kuryshev et al., 1996; Lee & Tse, 1997; Shipston et
al., 1996). In this respect, both AtT20 cells and adenohypophysial corticotrophs are
systems that could be useful for understanding the actions of adrenal corticosteroids
in nerve cells. This is of particular importance since glucocorticoids also exert
negative feedback inhibition at the hippocampal level (Meaney et al., 1988; Packan
& Sapolsky, 1990; Sapolsky et al., 1990). Furthermore, glucocorticoids (in high
concentrations) are known to have deleterious effects on the hippocampus (e.g.
causing atrophy of dendritic processes) (Sapolsky, 1996) and may also contribute to
HPA dsyfunction in normal aging (Lupien et al., 1998; McEwen, 1999). The
paraventricular nucleus of the hypothalamus is also a plausible site of glucocorticoid
negative feedback action (Itoi et al., 1987; Kwak et al., 1992; Ogasa et al., 1992;
Watanobe & Takebe, 1990). An important function of glucocorticoid feedback at the
hypothalamus is to downregulate the production of CRF and AVP (from
parvicellular neurons) (Herman et al., 1990; Itoi et al., 1987; Kwak et al., 1992;
Ogasa et al., 1992). The decrease in CRF and AVP signals from the hypothalamus
subsequently delimit ACTH secretion from anterior pituitary corticotrophs.
In sum, these studies will help to further the understanding of the pathophysiology of
psychiatric disorders, in particular, the effects of adrenal corticosteroids on excitable
tissues because these are relevant for the actions of steroids in psychiatric disorders.
7
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Furthermore, voltage-operated ion channels feature prominently in the
electrophysiological characteristics of adenohypophysial corticotrophs, resembling
neurons. As such, study of the role of these voltage-gated ion channels in
corticotrophs may contribute to the overall understanding of hormonal action
(particularly with respect to the interaction between glucocorticoids and ion
channels) in neurons.
Mechanisms of early glucocorticoid feedback
The early phase of glucocorticoid feedback inhibition involves the induction of
newly synthesised proteins. Nonetheless, how these putative glucocorticoid-induced
proteins inhibit stimulated ACTH secretion is still not fully understood.
One reason why there is not yet a unifying theme to explain early glucocorticoid
inhibition may be due to the differences in the characteristics of the experimental
models used and the lack of a clear definition of the time-scale of glucocorticoid
exposure employed by different workers. The differences in each study may in turn
modulate the magnitude as well as direction of the glucocorticoid (Johnson et al.,
1979). For instance, the majority of studies performed to date reports a lag time of
10-30 min after glucocorticoid administration for early inhibition (see section 1.1.2)
to be manifest in a variety of in vitro corticotroph models (Abou-Samra et al., 1986;
Brattin & Portanova, 1977; Dayanithi & Antoni, 1989; Gillies & Lowry, 1978;
Mahmoud et al., 1984; Mulder & Smelik, 1977; Portanova & Sayers, 1974;
8
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Widmaier & Dallman, 1984). However, Johnson and colleagues have reported a
virtually immediate action of glucocorticoids in AtT20 cells (Johnson et al., 1982)
while Familari and Funder failed to find fast or delayed inhibition (sub-components
within the time domain of the early phase; see section 1.1.2) in perifused primary
cultures of rat corticotrophs attached to cytodex beads (Familari & Funder, 1989).
Despite the discrepancies in the literature relating to early glucocorticoid actions, it is
of note that in studies investigating inhibition at the pituitary level in vivo,
glucocorticoids inhibit CRF- and insulin-stimulated ACTH release (within the time
domain for early delayed inhibition) in dogs (Keller-Wood, 1990; Keller-Wood &
Bell, 1988).
Several lines of evidence suggest that the synthetic glucocorticoid, dexamethasone
and the natural corticosteroids, Cortisol and corticosterone have different in vivo sites
of action cf (Keller-Wood & Dallman, 1984). Systemic administration of
dexamethasone and corticosterone has shown that dexamethasone binding is very
high in the pituitary and very low in the hippocampus, while corticosterone binding
reflects the reverse situation (De Kloet et al., 1975; McEwen et al., 1976; Rhees et
al., 1975). Thus, dexamethasone appears to act predominantly at the pituitary level
in vivo. However, this differential binding of corticosterone and dexamethasone is
much less striking in vitro than in vivo, suggesting a differential uptake of
dexamethasone and corticosterone by brain tissue (De Kloet et al., 1975; McEwen et
al., 1976). Recent evidence from adrenalectomized rats and mice suggests that
dexamethasone is extruded from brain by the multiple drug resistance (mrdla) gene-
encoded P-glycoproteins (De Kloet, 1997).
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Though not yet fully understood, the mechanisms underlying secretagogue-evoked
ACTH secretion involve multiple pathways and levels (Shipston, 1992), thus
providing numerous sites at which glucocorticoids may exert their inhibitory effect.
In particular, the mechanism of early glucocorticoid inhibition is likely to involve the
disruption of stimulus-secretion coupling, independent of any effects on ACTH
biosynthesis, storage, or degradation (Phillips & Tashjian Jr, 1982). This is evident
in the overwhelming majority of studies in which glucocorticoids predominately
inhibited stimulated, rather than basal ACTH secretion (Abou-Samra et al., 1986;
Clark & Kemppainen, 1994; Shipston et al., 1996; Woods et al., 1992). Studies of
early glucocorticoid inhibition in the mouse corticotroph tumour cell line AtT20
(Antoni et al., 1992; Phillips & Tashjian Jr, 1982; Woods et al., 1992) suggests that
paracrine interactions between different cell types of the anterior pituitary gland do
not appear to play an important role in early inhibition. Consequently,
glucocorticoids may directly target DNA elements within the corticotroph to
generate the putative proteins that characterise early glucocorticoid inhibition. The
following sections discuss the currently proposed mechanisms of early
glucocorticoid inhibition in the anterior pituitary corticotroph.
1.2.1 Modulation ofreceptor/sisnal transduction pathways
Previous work has reported a reduction of CRF plasma membrane binding sites
within 10 min of glucocorticoid exposure in primary cultures of enriched rat
corticotrophs (Childs & Unabia, 1990). Although such down-regulation is observed
in late inhibition (Childs et al., 1986; Pozzoli et al., 1996; Rivier & Vale, 1987;
10
Introduction
Schwartz et al., 1986), it is unlikely to be involved in early inhibition. Studies of late
glucocorticoid inhibition have reported inhibition of CRF-induced cAMP
accumulation (Bilezikjian et al., 1987; Bilezikjian & Vale, 1983) in vitro. In
contrast, other reports on CRF-stimulated cAMP accumulation in vitro and in vivo do
not support this hypothesis (Giguere et al., 1982; Kant et al., 1989). There is no
direct evidence for early glucocorticoid inhibition of CRF or AVP activation of
intracellular signal transduction pathways documented to date. Furthermore, ACTH
secretion may not necessarily be impaired when CRF receptors and cAMP responses
are downregulated c/(Aguilera et al., 1986). This suggests considerable plasticity of
intracellular signalling mechanisms downstream of G-protein coupled receptor-
effector coupling, which could be a site of glucocorticoid feedback inhibition.
Indeed, numerous studies have demonstrated that ACTH secretion stimulated by
direct activators of PKA or PKC is inhibited by glucocorticoids cf (Oki et al., 1991;
Phillips & Tashjian Jr, 1982; Woods et al., 1992). Moreover, glucocorticoids do not
prevent cAMP-induced activation of PKA (Miyazaki et al., 1984). Therefore, it is
plausible that the site of glucocorticoid inhibition is at a common juncture of
stimulus-secretion coupling, downstream to CRF or AVP receptor activation of
signal transduction pathways. Since Ca2+ plays a pivotal role in the regulation of
stimulated ACTH secretion (Antoni, 1986; King & Baertschi, 1990), it is possible





1.2.2 Suppression ofintracellular free Ca2+ responses
The link between a modulatory role for glucocorticoids and calcium handling in
corticotrophs was established in early in vitro studies [see (Antoni, 1986; Jones &
Gillham, 1988; Kraicer et al., 1969)]. In a more recent study (Oki et al., 1991), Oki
and co-workers reported, using perifused rat corticotrophs, that the sustained phase
of ACTH secretion stimulated by CRF, AVP, oxytocin or combination of
9+
secretagogues that is dependent on Ca influx through voltage-gated (predominantly
9 I-
dihydropyridine-sensitive, L-type) Ca" -channels, was inhibited by glucocorticoids.
However, the initial phase of secretion elicited by AVP or oxytocin (which was
dependent on inositol triphosphate-stimulated intracellular Ca2+) was not sensitive to
9-f"
the inhibitory action of glucocorticoids, implicating the reduction of Ca" influx
9 I
through L-type Ca -channels by glucocorticoids. In addition, when voltage-
dependent Ca2+ entry is bypassed in electrically permeabilised AtT20 cells, early
9_i
glucocorticoid inhibition of Ca -mediated ACTH secretion was prevented (Woods
et al., 1994). Since early glucocorticoid inhibition can be blocked by depolarization
and as voltage-dependent ion channels have a fundamental role in the regulation of
• 9+
ACTH secretion, it is conceivable that changes of intracellular free Ca levels
([Ca2+]0 may occur upon treatment with glucocorticoids.
Antoni and co-workers reported evidence for the restriction of Ca2+ mobilisation by
glucocorticoids in studies examining fura-2 fluorescence measurements of [Ca2+]i in
single AtT20 corticotrophs (Antoni et al., 1992). The synthetic glucocorticoid
9_i_
dexamethasone suppressed CRF-stimulated (but not basal) intracellular Ca
transients that were dependent on Ca2+ influx through L-type Ca2+-channels in
12
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roughly 50% of dexamethasone-treated cells. A similar reduction in CRF-stimulated
Ca2+ transients was reported in about 25% of single AtT20 cells analyzed after
treatment with dexamethasone (Castellino et al., 1992). Another study reportedly
found no suppression of intracellular free Ca2+ transients in populations of AtT20
cells attached to coverslips (made from the plastic substrate Aclar) after
dexamethasone treatment (Clark & Kemppainen, 1994). However, it was not tested
whether the inhibitory effect of dexamethasone on ACTH secretion still persisted in
Aclar attached cells. Therefore, such a culture system may have altered the
characteristics of early glucocorticoid inhibition. Furthermore, it appears that only a
proportion of AtT20 cells may secrete ACTH in response to CRF stimulation in
single cell studies ofACTH secretion cf(Canny et al., 1992). Hence, there may have
been a higher proportion of cells not responsive to CRF, resulting in changes of
I
[Ca ]i in the functionally relevant cell population being masked.
94- •
Overall, the importance of Ca transients in the regulation of ACTH secretion and
the regulation of Ca2+ transients by CRF and glucocorticoids requires further
understanding. Nonetheless, it would appear that the studies where the methods for
9+
ACTH secretion analysis and intracellular Ca recordings can be closely correlated,
a change in the characteristics of CRF-induced Ca2+ transient after dexamethasone
94-
treatment resulting in a reduction of gross [Ca ]i over time, is apparent. In addition,
94-
reduction of [Ca ][ has also been proposed as a mechanism in other models of early
glucocorticoid inhibition such as B-lymphocytes (Dennis et al., 1987), basophilic
leukemia cells (Her et al., 1990) and pancreatic islet (3-cells (Billaudel et al., 1984).
13
Introduction
1.2.3 Hyperpolarization ofthe membrane potential
The connection between glucocorticoids and the membrane potential was mooted by
studies showing that corticosteroid hormones could modulate hippocampal neuronal
excitability. It was demonstrated that glucocorticoids could hyperpolarize the
membrane potential within 30 min in hippocampal CA1 neurons (Joels & de Kloet,
1989; Kerr et al., 1989). Such modulation of the plasma membrane potential could
indirectly block Ca2+ influx, thereby altering the Ca2+ homeostasis. A previous
electrophysiological study in AtT20 D16:16 cells using whole cell patch clamp
recordings has suggested that glucocorticoids limit Ca2+ influx indirectly through
enhancement of a transient, outward A-type K+ current (Pennington et al., 1994).
Importantly, pharmacological inhibition of K+ currents with blockers like
tetraethylammonium and 4-aminopyridine (which selectively blocks transient A-
currents), markedly attenuated the inhibitory action of glucocorticoids on CRF-
evoked ACTH secretion and enhances Ca2+ influx in AtT20 D16:16 cells (Antoni et
al., 1992; Pennington et al., 1994; Wang & Greer, 1995; Woods et al., 1994). The
study (Pennington et al., 1994) also demonstrated that ACTH secretion elicited by
high extracellular K+ concentrations was also largely resistant to dexamethasone
inhibition in AtT20 cells.
Furthermore, glucocorticoids reportedly enhance other types ofK+ currents within 3h
in hippocampal neurons cf (Joels & de Kloet, 1992). These include the slow Ca2+-
dependent K+ conductance (Iahp) and the Ca2+-independent K+ conductances (Ik)
(Nicoll et al., 1990). Iahp slowly inactivates the K+ conductance at the end of a
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depolarization period in CA1 pyramidal neurons of the hippocampus while Ik is
responsible for the hyperpolarization ofCA1 pyramidal neurons (Nicoll et al., 1990).
Another study has reported that Kvl mRNA, encoding a voltage-dependent K+-
channel, was induced by glucocorticoids within 40 min in the anterior pituitary gland
as well as clonal GH3 cells. However, no induction was observed in AtT20 (strain
not reported) cells (Levitan et al., 1991). Collectively, these data pointed to the
possible involvement of K+-channels in early glucocorticoid inhibition. Recent
electrophysiological data from AtT20 cells have shown that selective blockage of
BK-type K+-channels (large-conductance Ca2+-activated K+-channels) by the
synthetic glucocorticoid dexamethasone prevented the early inhibition of ACTH
secretion by dexamethasone (Shipston et al., 1996).
1.2.4 Working Hypothesis : the AtT20 corticotroph model ofearly slucocorticoid feedback
inhibition
The mouse corticotroph tumour cell line, AtT20 is a potentially useful model system
to characterize corticosteroid action in adenohypophysial corticotrophs. Both cell
types are electrically active and their functions are closely coupled to ion channel
activity regulated by membrane voltage (Adler et al., 1983; Reisine, 1989;
Suprenant, 1982). Importantly, AtT20 cells have been shown to retain the main
hallmarks of early glucocorticoid inhibition previously observed in rat corticotrophs
(Woods et al., 1992). These defining features are onset within 2 h after exposure to
glucocorticoids, mediation through Type II glucocorticoid receptors and requirement
for mRNA and protein synthesis. However, the main anomaly of the action of
glucocorticoids in these tumour cells is that while synthetic glucocorticoids (like
15
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dexamethasone) are effective, natural glucocorticoids (like corticosterone and
Cortisol) are virtually inactive (Svec, 1984; Svec & Harrison, 1979; Woods et al.,
1992). The reasons for this phenomenon are not well understood. Woods and
colleagues demonstrated a small but significant inhibition of CRF-stimulated ACTH
secretion in AtT20 cells in the presence of glycyrrhetinic acid, an inhibitor of 11P-
hydroxysteroid dehydrogenase (lip-HSD) (Woods et al., 1992). lip-
hydroxysteroid dehydrogenase (which exist in two distinct isozyme, 1 ip-HSD-1 and
lip-HSD-2) catalyses the conversion of the active glucocorticoids corticosterone
and Cortisol to inert 11 keto-products (11- dehydrocorticosterone, cortisone) (Seckl,
1997; Stewart & Sheppard, 1992). Accumulating evidence suggests that lip-HSD-1
(the isoform that possesses bidirectional activity) is widely expressed in the brain,
including the pituitary (Seckl, 1997). Therefore, it is possible that in AtT20 cells,
corticosterone is metabolized into its biologically inactive form by lip-HSD,
accounting for its lack of discernible inhibitory effect on stimulated ACTH secretion.
Nonetheless, AtT20 cells on the whole offer a potentially useful starting point for the
characterisation of glucocorticoid-induced proteins and their role in the signal
transduction pathways underlying early glucocorticoid feedback inhibition in vivo
(that is in normal corticotrophs).
The following mechanism(s) for glucocorticoid early feedback inhibition using
AtT20 cells as a model has been proposed based on experimental evidence described
in section 1.2 and elsewhere.
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CRF is the major physiological stimulus for ACTH secretion from anterior pituitary
corticotrophs (Antoni, 1986). Current evidence suggests that the CRF1 receptor
subtype is expressed in normal rat corticotrophs (Chalmers et al., 1995; Pozzoli et
al., 1996) as well as in AtT20 cells (Vita et al., 1993). CRF1 receptor is tightly
coupled to the Gs-adenylate cyclase cascade and does not bring about any primary
changes in polyphosphoinositide metabolism (Xiong et al., 1995). In AtT20 cells,
CRF-stimulated cAMP and the subsequent activation of protein kinases by cAMP
forms the major intracellular signalling system (Reisine et al., 1985; Schecterson &
McKnight, 1993).
Figure 1.2 illustrates the main intracellular signalling pathways regulating CRF-
stimulated ACTH secretion and the proposed mechanisms by which early
glucocorticoid inhibition occurs in AtT20 cells. Note that although this model is
largely derived from work in AtT20 cells, it also incorporates data from normal rat
corticotrophs. The major difference between normal and tumoural corticotrophs is
the presence of cAMP-activated caffeine/ryanodine-sensitive internal Ca2+ stores in
normal corticotrophs (Abou-Samra et al., 1987; Won & Orth, 1990). This internal
Ca pool appears to be negligible in AtT20 cells, which relies exclusively on the
influx of extracellular Ca2+ to stimulate ACTH secretion (Reisine, 1989; Richardson,
1983; Richardson, 1986).
The sequence of events begins with ligand-bound CRF1 receptor activation of
adenylate cyclase mediated through Gs-a. The ensuing cAMP production




Working model of early glucocorticoidfeedback inhibition in AtT20
corticotrophs
Figure 1.2: CRF signalling pathway in AtT20 cells: CRF-receptor (R) coupling
induces cAMP production through Gs subunit activation of adenylate cyclase (AC).
Subsequent cAMP-dependent phosphorylation activates L-type Ca2+ - channel (L-
channel) whilst inhibiting BK-channel. The resulting Ca2+influx elicits ACTH
secretion. Glucocorticoid inhibitory pathway: Glucocorticoid binds to intracellular
Type II receptors to induce synthesis of new mRNA(s) and protein(s), which blocks
the inhibition of BK-channel caused by cAMP-dependent phosphorylation. ATP:
Adenosine triphosphate; N: nucleus; GR: Glucocorticoid receptor. See section 1.2.4
for more detailed description.
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well as AtT20 cells (Guild & Reisine, 1987; Litvin et al., 1984; Reisine, 1989)] and
accumulation activates the cAMP-dependent protein kinase (protein kinase A, PKA),
which has been found to have at least 2 functionally significant targets [many more
may well exist (Lory & Nargeot, 1992; Rougon et al., 1989)]. These targets are the
2_|_ _j_ #
L-type Ca~ channels (L-channels) and the BK-type K -channels (BK-channels) in
AtT20 cells. PKA may activate L-channels increasing the probability of channel
opening and prolonging the opening state of L-channels upon depolarization (Wang
et al., 1993) through PKA-dependent phosphorylation of either the channel subunits
directly or other closely associated channel proteins (Chamet et al., 1995; Puri et al.,
2 j j
1997; Rougon et al., 1989). Modulation of Ca -activated K -channels by protein
phosphorylation (including by PKA) (Ewald et al., 1985; Reinhart et al., 1991) has
been extensively documented [reviewed in (Levitan, 1994; Levitan, 1999)].
Specifically, previous work in AtT20 cells suggests that PKA-mediated
phosphorylation may inhibit the opening of BK-channels (Shipston et al., 1996).
Taking together the effect of PKA on L-channels and BK-channels (Luini et al.,
1985; Shipston, 1995; Shipston et al., 1996), it is plausible that the cycling of the
membrane potential, which occurs spontaneously at 37°C in AtT20 cells (Adler et
al., 1983; Antoni et al., 1992; Suprenant, 1982), is shifted towards depolarization and
2_|_
prolonged Ca channel openings (with no significant phosphorylation or G protein-
mediated alterations in the function of other ion channels). Note that in normal
corticotrophs, there are likely to be additional components of CRF action involving
2"bthe mobilisation of Ca from caffeine-sensitive internal stores (Abou-Samra et al.,
1987; Antoni, 1994; Antoni, 1995). The resulting Ca2+ influx raises the [Ca2+]i and
triggers the calcium sensor element of the exocytotic apparatus, stimulating the
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secretion of ACTH. Although there is evidence that cAMP-mediated
phosphorylation acts in synergy with Ca2+to stimulate ACTH release (Guild, 1991),
the exact mechanism(s) are not yet fully resolved.
Early glucocorticoid inhibition involves activation of intracellular Type II
glucocorticoid receptors (which are ligand-dependent transcription factors) that
regulate gene transcription from target genes. Thus, glucocorticoids upon binding to
Type II receptors in corticotrophs, induce the synthesis of new mRNAs and proteins,
which mediate the inhibitory effects of glucocorticoids. Evidence obtained to date
suggests that one such protein is likely to be the multifunctional Ca2+-binding
protein, calmodulin. The glucocorticoid-induced protein(s) blocks the inhibition of
BK-channels by PKA-mediated phosphorylation (Shipston et al., 1996), thereby
allowing the repolarization of the membrane potential mediated by these channels.
Consequently, [Ca2+]i drop as the L-channels close, leading to a cessation of CRF-
stimulated ACTH secretion.
A particular aspect of this CRF-activated pathway concerns the intracellular Ca2+-
mediated feedback regulation of secretagogue-induced cAMP response. An increase
of intracellular cAMP levels elicited by secretagogues (e.g. CRF) produces a rise in
[Ca2+]i known to be essential for triggering ACTH secretion. This rise in [Ca2+]i in
turn downregulates the agonist-induced cAMP response through inhibition of
adenylate cyclase and cAMP-degrading phosphodiesterase (Antoni, 1996).
j
Specifically, studies in AtT20 cells has suggested that the targets for this Ca -
mediated feedback are the type 9 adenylate cyclase (through calcineurin) (Antoni et
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al., 1995; Paterson et al., 1995) and Ca2+/calmodulin-activated phosphodiesterase
(Ang & Antoni, 1996). Additionally, Ca2+ may activate voltage-gated K+-channels
(specifically BK-channels) in AtT20 cells (Shipston et al., 1996). This negative
mode of Ca2+ inhibits cAMP synthesis whilst promoting cAMP degradation, and also
cause hyperpolarization of the membrane potential. All these events act in concert to
repolarize the membrane potential, downregulate the intracellular cAMP levels (and
9+ •
cAMP-dependent phosphorylation) and Ca" levels, thereby terminating the
secretory response (Antoni, 1996). Given that the early phase of glucocorticoid
inhibition is likely to involve calmodulin, it is plausible that early glucocorticoid
inhibition involves amplification and sensitization of the cellular machinery to the
negative mode of operation ofCa2+ (Antoni, 1996).
This section has described putative mechanisms of early glucocorticoid feedback
inhibition operable in AtT20 cells, based mostly on work done in AtT20 cells. The
precise molecular mechanisms await to be resolved. Furthermore, there may also be




1.3 Aims and Objectives of the Thesis
The principal aim of this thesis is to investigate in normal rat corticotrophs, the
validity of a model of early glucocorticoid feedback inhibition developed in AtT20
cells.
1.3.1 Role ofcalmodulin as primary mediator ofearly glucocorticoid inhibition
The first hint that the early inhibitory action of glucocorticoids may involve
calmodulin came from studies that demonstrated a suppression of intracellular
calcium transients by glucocorticoids (Antoni, 1986; Jones & Gillham, 1988). The
subsequent search for the mRNAs of calcium-binding proteins in AtT20 cells
revealed that steady state mRNA levels for the calmodulin (the multifunctional
calcium receptor protein) was significantly increased (Shipston & Antoni, 1992;
Woods et al., 1992). The steady state calmodulin mRNAs increased approximately
10-fold within 45 min of dexamethasone treatment while calmodulin protein levels
rose 3-fold above control after a 90min exposure to dexamethasone. Current
evidence suggests that there are 3 known calmodulin genes in rats (Gannon &
McEwen, 1994; Nojima, 1989) as well as in humans (Fischer et al., 1988), which
encode the same protein, but are the products of different genes with distinct 5' and 3'
non-coding region. Interestingly, the glucocorticoid-inducible calmodulin appears to
be largely specific to Type II calmodulin mRNA , which induction can be blocked by
protein synthesis inhibitors (Shipston, 1992). Recent reports suggest that the
approximately 1.6kb mRNA transcript detected in AtT20 cells (Shipston, 1992;
Shipston & Antoni, 1992) is likely to correspond to the rat Type I calmodulin gene
(Sola et al., 1996; Ye & Berchtold, 1997), and not the rat Type II calmodulin gene.
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The calmodulin mRNA transcripts corresponding to the other 2 rat genes (Type II
and III) were only present in very low levels which precluded accurate quantification
(Shipston, 1992).
Other previously proposed potential mediators of early glucocorticoid inhibition,
namely calbindin, chromogranin A and lipocortin (annexin) I were not found to be
induced by dexamethasone within the time frame of early glucocorticoid inhibition
by protein immunoblots and Northern blot hybridization studies for known
sequences of these proteins (Antoni et al., 1992; Woods et al., 1992). The actin
cross-linking protein, caldesmon, has also been associated with glucocorticoid
inhibition since it was observed that glucocorticoids increased the cellular content of
this protein in AtT20 cells. However, this induction was apparent only after more
that 6 h of glucocorticoid exposure, beyond the time interval for early glucocorticoid
inhibition (Castellino et al., 1992).
Induction of calmodulin by glucocorticoids has been proposed as a generic
mechanism involved in early glucocorticoid inhibition of calcium signalling in
several systems. These include lymphocytes (Baughman et al., 1991; Dowd et al.,
1991) and corticotrophs (Antoni et al., 1992; Shipston & Antoni, 1992). Although
direct evidence for a primary mediatory role for calmodulin is still not available,
several indirect lines of evidence suggest that calmodulin may indeed have a central
role in early glucocorticoid inhibition. Firstly, glucocorticoids induce elevation in
calmodulin mRNA and protein levels in AtT20 cells within the time frame of early
glucocorticoid inhibition. Conversely, the simultaneous exposure of AtT20 cells to
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glucocorticoids and CRF prevented glucocorticoid inhibition of stimulated ACTH
secretion as well as glucocorticoid induction of calmodulin mRNA (Shipston &
Antoni, 1992). Secondly, the inhibition of calcineurin (calmodulin-activated
phosphatase), which has been proposed as an important feedback inhibitor of
calcium action in excitable cells (Armstrong, 1989), antagonises early glucocorticoid
inhibition in AtT20 cells ((Shipston et al., 1994) and see section 4.3.1) Finally, a
recent study (Ribar et al., 1995) has demonstrated a direct role for elevated
calmodulin levels in the inhibition of stimulated insulin secretion from pancreatic p-
cells.
This indirect evidence clearly suggest a role for calmodulin in early glucocorticoid
feedback inhibition in corticotrophs. Therefore, this first part of the thesis attempts
to provide confirmation for the role of calmodulin in the inhibitory action of
glucocorticoids through over-expressing calmodulin in AtT20 cells. This will be
done in 2 ways, by generating constitutive calmodulin over-expression as well as
inducible calmodulin over-expression systems in AtT20 cells. These over-
expression systems will then be used to study both basal and stimulated ACTH
secretion to see if artificially elevated calmodulin levels have any effect on ACTH
secretion in AtT20 cells.
1.3.2 Role ofpotassium channels in slucocorticoid inhibition
Previous work in AtT20 cells has shown that dexamethasone treatment enhances a
fast activating and transient outward (A-type) K+ current by a mechanism requiring
protein synthesis. The enhancement of this voltage-regulated K+ current may blunt
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the effects of depolarization on the voltage-gated L-channels (Pennington et al.,
1994). Importantly, pharmacological studies in AtT20 cells has demonstrated that
inhibition of K+ currents (including A-type K+ currents) attenuates the inhibitory
action on CRF-evoked ACTH secretion and enhances Ca2+ influx (Antoni et al.,
1992; Pennington et al., 1994; Wang & Greer, 1995; Woods et al., 1994). These
94-
studies indicated that the apparent glucocorticoid suppression of increases in [Ca ]i
I j
stimulated by CRF could be mediated through K -channels, in particular, Ca -
activated K+-channels. This class of K+-channels has been suggested to be closely
94"
associated with Ca -channels in the plasma membrane [in a variety of voltage-
operated secretory systems; (Gola & Crest, 1993)], and may therefore be involved in
the localised repolarization (hyperpolarization) of membrane potential following
membrane depolarization and Ca2+ influx (Heyward et al., 1993; Iijima et al., 1990;
Robitaille & Charlton, 1992). Analysis of the K+ and Ca2+ currents in
dexamethasone-treated AtT20 cells (Pennington et al., 1994; Shipston et al., 1996)
have indicated that BK-channels are modulated by dexamethasone. Shipston et al.
demonstrated that CRF and CPT-cAMP inhibited an outward current by reducing the
open probability of BK-channels (Shipston et al., 1996). This effect was apparently
mediated by PKA since CPT-cAMP is an activator ofPKA and that the pretreatment
ofAtT20 cells with Rp-cAMPS (a PKA inhibitor) significantly diminished this effect
of CRF. Importantly, dexamethasone pretreatment abolished the inhibitory effect of
both CRF and CPT-cAMP on the K+ current. Furthermore, dexamethasone
inhibition ofACTH release was completely reversed by relatively potent BK-channel
inhibitors such as iberiotoxin (Shipston et al., 1996) and charybdotoxin (Woods et
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al., 1992). These data therefore strongly suggest that BK-channels are common
targets of cAMP and glucocorticoid-induced proteins in AtT20 cells.
In normal rat corticotrophs, CRF-activated signalling pathways involve the cAMP-
dependent PKA pathways (Kuryshev et al., 1995; Kuryshev et al., 1995; Lee & Tse,
1997). Several lines of evidence suggest that K+-channels are also likely to be
important in the action of early glucocorticoid feedback inhibition of stimulated
ACTH release in normal corticotrophs. For instance, preliminary studies in rat
anterior pituitary cultures showed that elevation of extracellular KC1 concentrations
reduced the efficiency of dexamethasone inhibition (Antoni, 1996). Other
depolarizing agents (such as the sodium channel blocker, veratridine) could also
elicit ACTH secretion that was partially (Antoni & Woods, 1992) or completely
resistant to dexamethasone inhibition (Halilimanabat et al., 1995). Furthermore,
glucocorticoids have also been found to modulate voltage-gated K+-channel mRNA
expression in the anterior pituitary (Levitan et al., 1991) and also in heart (Levitan et
al., 1996; Takimoto & Levitan, 1994).
Consequently, the aim of this part of the thesis is to examine the role of K+-channels
in early glucocorticoid inhibition in non-tumoural corticotroph cells. In particular,
whether BK-channels are also essential components of the early glucocorticoid
inhibitory pathway. Experiments will be chiefly carried out in primary cultures of rat
anterior pituitary cells. The effects of K+- channel blockers on secretagogue-(mainly
CRF) induced ACTH secretion will be investigated.
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1.3.3 Role ofyrotein phosphorylation in glucocorticoid inhibition
One of the plausible sites for glucocorticoid inhibition is early in the CRF-activated
signalling pathway. The generation of cAMP signals (see section 1.2.4) by CRF
serves to propagate the activation signals through cAMP-dependent phosphorylation
by PKA. Thus, blockade of this cAMP-activated phosphorylation step will truncate
the signal transduction pathway induced by CRF, resulting in a disruption of the
ACTH secretory process. Protein phosphatases are plausible candidates that could
reverse the effects of protein phosphorylation. The main types of protein
phosphatases (PP), PP1, PP2A, PP2B (calcineurin) and PP2C have all been
previously described in AtT20 cells (Antoni et al., 1993). Of note is the
9+
Ca /calmodulin-activated protein phosphatase 2B, known as calcineurin. It has
been shown to dephosphorylate a specific region of the RII subunit ofPKA, which is
a poor substrate for the other protein phosphatases (Blumenthal et al., 1986).
Therefore, it is conceivable that calcineurin may even modulate PKA activity. In
wider terms, calcineurin may modulate PKA-phosphorylated targets like the L-type-
2"bCa channels, the BK-channels (section 1.2.4) or some other as yet undefined
component that acts in synergy with Ca2+ to elicit ACTH secretion (Guild, 1991).
The immunosuppressants FK506 and cyclosporin A (CsA) are potent inhibitors of
calcineurin (Liu et al., 1991). FK506 and CsA must bind to their intracellular
immunophilins, FK-binding protein-12 (FKBP12) and cyclophilin A respectively
prior to binding and inhibiting calcineurin activity (Liu et al., 1991).
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Previous studies have indicated that calcineurin has an inhibitory role in stimulus-
secretion coupling in AtT20 cells since FK506 and CsA stimulated ACTH secretion
by AtT20 cells (Antoni et al., 1993). Subsequent studies have shown that FK506
enhanced the ACTH secretory response to CRF and that this secretion was less
effectively inhibited by the synthetic glucocorticoid (Shipston et al., 1994). The
effect of FK506 on dexamethasone-inhibited ACTH release was blocked by the
FK506 antagonist drug, L685,818 (Shipston & Antoni, unpublished). These data
provided strong pharmacological evidence that calcineurin played an important role
in early glucocorticoid inhibition of stimulated ACTH secretion in AtT20 cells
(Antoni et al., 1995; Antoni et al., 1993).
As part of a concerted effort to elucidate the molecular mechanisms of early
glucocorticoid inhibition in normal rat corticotrophs, the role of calcineurin in ACTH
secretion and glucocorticoid inhibition of stimulated ACTH release was investigated
in primary cultures of rat anterior pituitary cells. Northern and Western blot analysis
has revealed that FKBP-12 and cyclophilin A mRNA and protein is present in rat
anterior pituitary tissue (Ohye et al., 1998). Therefore, the use of FK506 and CsA as
pharmacological probes will shed light on any potential role that calcineurin may




In sum, the principal aim of this thesis is to examine and verify the validity of a
model of the cellular mechanism(s) underlying early glucocorticoid established in
mouse corticotroph tumour cell, AtT20. The specific aims are as follows:
1) To confirm the hypothesis that early glucocorticoid feedback inhibition
involve the induction of calmodulin., which acts as the primary mediator of
the inhibitory actions of glucocorticoids.
2) To investigate, in normal (non-tumoural) rat corticotrophs,, the role of K+-
channels in the signal transduction pathway of early glucocorticoid inhibition.
In particular if BK-channels, which have been found to be an integral part of
glucocorticoid inhibition in the AtT20 system, are also important components
of glucocorticoid inhibition in normal corticotrophs.
3) To examine the role of protein phosphorylation, specifically the involvement
of calcineurin (calcium-activated protein phosphatase) in glucocorticoid









Male Wistar rats (120-200g) obtained from Charles River Ltd (Margate, Kent, UK)
were used for all the experiments with cultured rat anterior pituitary cells. The rats
were caged singly (to minimise stress-induced activation of the hypothalamic-
pituitary-adrenal axis).with free access to pelleted food and tap water in a light
(lights on at 0500h , off at 1900h) and temperature-controlled (22°C) environment 24
h prior to the setting up of primary cultures. On the day of preparation of primary
cultures (see section 2.2), rats were routinely sacrificed by decapitation before
1030h.
2.1.2 AtT20 cells, mouse anterior pituitary corticotroyh tumour cell line
AtT20 D16:16 cells used were originally obtained from Dr. S. L. Sabol, NIH,
Bethesda, Maryland, USA (Sabol, 1980). Cells were maintained as monolayers in
Dulbecco's modified Eagle's medium (DMEM, GibcoBRL, Life Technologies Ltd,
Paisley, UK) containing 4.5g glucose/L and supplemented with 10% foetal calf
serum (FCS, Harlan Sera-lab, Sussex, UK) at 37°C in a humidified atmosphere of
95% air and 5% CO2. Cells were passaged every 7 days after reaching 70-80%
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confluency in 75cm2 flasks (Costar, High Wycombe, Buckshire, UK) using Hank's
balanced salt solution without Ca2+ and Mg2+ (HBSS, GibcoBRL, Life Technologies
Ltd, Paisley, UK) containing 0.1% w/v EDTA. After pelleting at 200g for 5 min, 1 x
106 cells were reseeded into a 75cm2 flask. All experiments were performed on cells
between passage 16 and 30.
2.1.3 Biochemicals
Steroids: Corticosterone (RU 3039) was from Roussel-Uclaf (Romainville, France),
dexamethasone was from Sigma-Aldrich (Poole, Dorset, UK). Working steroid
stocks were dissolved in dimethylsulphoxide (DMSO) at a concentration of lOmM
and stored at -20°C before dilution in the appropriate cell incubation medium on the
day of experiment.
Peptides: Rat 41-residue corticotrophin-releasing factor (CRF), arginine vasopressin
(AVP) and human adrenocorticotrophin hormone (ACTH1.39) were obtained from
Bachem UK Ltd (Saffron Walden, Essex, UK) or Peninsula Laboratories Ltd (St
Helens, Merseyside, UK). Working stock peptides were stored as O.lmM (CRF),
ImM (AVP) or 0.25pM (ACTH1.39) stocks in 0.01M HC1 (including ImM ascorbate
where appropriate to prevent methionine oxidation) at -70°C. Bovine brain
calmodulin was from Sigma and was kept as 20pM stock in 0.1% w/v bovine serum
albumin (BSA, Sigma A-4378) at -40°C.
K*-channel inhibitors: Tetraethylammonium hydrochloride (TEA) and 4-
aminopyridine (4-AP) were obtained from Aldrich Chemical Co. (Gillingham,
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Dorset, UK). Scorpion charybdotoxin was from Peptide Institute Inc. (Scientitic
Marketing Associates, Barnet Herts., UK), apamin (from bee venom) and astemizole
were from Sigma while clofilium tosylate was from RBI (Sigma, UK). E4031 was a
generous gift from Eisai Chemical Co. Ltd (Kashima-gun, Ibaraki-ken, Japan) while
dofetilide (UK-68,798) was generously provided by Pfizer Central Research,
Sandwich, UK (Gwilt et al., 1991). WAY-123,398 was a generous gift from Dr
Walter Spinelli, Wyeth-Ayerst Research, Princeton, NJ, USA (Spinelli et al., 1992)
while chromanol 293B was generously provided by Dr H.-J. Lang, Hoechst A.G.,
Frankfurt/Main, Germany (Busch et al., 1996).
Stock solutions of the K+-channel inhibitors stored at -20°C were as follows: 500mM
TEA, lOmM E4031, O.lmM charybdotoxin (stored at -70°C) and ImM apamin were
made up in UV-irradiated double distilled water; lOmM dofetilide in acidified saline;
lOOmM 4-AP and lOmM WAY-123,398 in 0.1M HC1; astemizole, clofilium and
chromanol 293B in DMSO.
Primary antisera: Sheep anti-ACTH antiserum was a generous gift from Prof PJ
Lowry, University of Reading, Berkshire, UK. Rabbit anti-cAMP antiserum (AL-
43) was generously supplied by Dr A Baukal and Dr KJ Catt (NICHD, National
Institutes ofHealth, Bethesda, MD, USA).
cDNA clones: A cDNA clone for normal and mutant chicken calmodulin (0.76kbp
insert in Ncol/Xbal site of pCaMPL (Putkey et al., 1987)) was generously provided
by Prof AR Means (Dept of Pharmacology, Duke University Medical Centre, North
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Carolina, USA). A cDNA clone for chicken calmodulin (0.28kbp insert in Hindlll
site of pGEM-1) was a generous gift from Dr DR Dowd, Arizona Cancer Center,
Tuscon, Arizona, USA (Dowd et ai, 1991).
Molecular biology reagents: TRIZOL® Reagent (GibcoBRL) was used for single-
step isolation of total RNA. Bacto-tryptone, bacto-yeast extract and agar were
obtained from Oxoid, Unipath Ltd, Basingstoke, Hampshire, UK. All restriction
enzymes and nucleotides were from Boehringer Mannheim UK (Lewes, East Sussex,
UK), Pharmacia Biotech (St. Albans, Hertfordshire, UK) or GibcoBRL. All other
reagents were from Sigma (Molecular Biology Grade) unless otherwise stated.
Miscellaneous: (-)BayK8644 (RBI), puromycin, D-ribofluranosylbenzimidazole
(DRB), doxycycline and activator-deficient bovine brain cyclic-nucleotide
phosphodiesterase 1 (PDE1) were from Sigma. Rolipram was from Schering A.G.
(Berlin, FRG). The following compounds were generous gifts from the
corresponding companies: FK506 (Fujisawa GmbH, Munich, Germany); cyclosporin
A (Novartis, UK); L685,818 (Merck, Rahway, NJ, USA). 8-(4-
chlorophenylthio)adenosine-3',5'-cyclic-monophosphate (CPT-cAMP) was from
Biolog Life Science Institute (Bremen, FRG).
Stock solutions of the following compounds and the corresponding storage
temperature: 5mM (-)BayK8644 (-20°C) and lOOmM rolipram in DMSO (-40°C);
2mM FK506, 2mM cyclosporin A and 50mM L685-818 in ethanol and stored at -
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70°C; 33mM DRB in ethanol (4°C); 50mM CPT-cAMP and 37mM puromycin were
dissolved in UV-irradiated double distilled water and kept at -40°C.
All other materials were obtained as described in the relevant methods or results
section. General chemicals were from BDH (Poole, Dorset, UK) or Sigma and of the
highest analytical grade available.
2.2 Primary culture of rat anteriorpituitary cells
After decapitation of the rats (see section 2.1.1), the anterior pituitary glands were
collected under sterile conditions and placed in a plastic Petri dish so that the ventral
surfaces of the glands contacted the bottom of the dish. The glands were chopped
twice (the second time after 90° rotation of the specimen platform) on a hand-
operated Mcllwain tissue-chopper setting 0.5mm and lowest blade force. The tissue
segments were incubated in HBSS without Ca2+ and Mg2+ (GibcoBRL)
supplemented with 25mM HEPES pH7.4, 0.15mM CaCl2, 0.15mM MgSOzg
0.5mg/ml trypsin, 0.01pg/ml DNase I (Sigma) and 0.25% w/v BSA (Sigma A-7906)
for 30min at 37°C under constant shaking at 250 cycles/min on a IKA Vibrax orbital
shaker. Following trypsinisation, 200pl of 10 kallikrein unit/ml Trasylol® (Bayer,
UK) was added and the tissue segments were triturated with a 1ml Gilson pipette tip
attached to the end of a 5ml polystyrene pipette for 10 min. The suspension was then
filtered through a 70pM nylon mesh and centrifuged at 200g for 10 min. The
pelleted cells were resuspended in 5ml HBSS supplemented with 25mM HEPES
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pH7.4, 0.15mM CaCl2, 0.15mM MgSC>4, O.Olpg/ml DNAse I, 0.25mg/ml soybean
trypsin inhibitor (Sigma), recentrifuged and suspended in DMEM (containing 4.5g
glucose/L) supplemented with 2.5% FCS (Harlan Sera-lab) and 7.5% horse serum
(Sigma H-l 138). Cell viability as assessed by Trypan Blue exclusion was over 95%.
Approximately 5 x 104 cells per well were plated in 24 -well plates (Falcon) and
cultured in DMEM containing 2.5% FCS and 7.5% horse serum or serum-free media
(DMEM containing insulin-transferrin-sodium selenite media supplement (Sigma),
42pg/ml fibronectin (Sigma) and 3% BSA). Cells were cultured in a humidified
incubator with 95% air and 5% CO2 at 37°C for 4 days before being used for ACTH
secretion experiments.
Static ACTHsecretion experiments
Primary cultures of rat anterior pituitary cells or AtT20 cells were cultured in 24 -
well plates (see section 2.2) for 4 and 5 days respectively before being used for
ACTH secretion studies.
Figure 2.1 is the schematic representation of a typical experimental procedure for an
ACTH secretion experiment. Prior to experimental manipulation, cells were washed
twice and maintained in DMEM containing 25mM HEPES (pH7.4) and 0.25% BSA
for 1 h at 37°C. Cells were pretreated with steroids or vehicle for 2 h at 37°C after
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Figure 2.1: Schematic representation of a generic procedure for ACTH secretion
experiments. Cells were preincubated in DMEM (Medium) at 37°C for 1 h after
being washed twice in DMEM. Steroids (either dexamethasone ot corticosterone)
was administered for 2 h at 37°C. In experiments where drugs (e.g. K+-channel
blockers and Ca2+-channel activators) were used, cells were treated with the
respective drugs during the last 30 min of steroid pretreatment, before cells were
challenged with stimulus (CRF, AVP or CPT-cAMP). The corresponding drugs
were again administered during stimulation of ACTH secretion by the secretagogue
(stimulus) for 30 min or 1 h, depending on the cell type used (see section 2.3).
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channel activators, Ca2+-channel inhibitors and immunosuppressants were introduced
30 min before and during stimulation with secretagogues (refer to respective Figure
legends for the treatment protocol of other drugs). The duration of secretagogue
challenge was 30 min and 1 h for experiments with AtT20 cells and cultured rat
anterior pituitary cells respectively. Cells were challenged with secretagogues at
37°C in a shaking water bath to enhance ACTH release. Medium containing the
secreted ACTH was collected and spun briefly at 200g to pellet any floating cells and
the supernatant used for determination ofACTH by radioimmunoassay.
2.3.1 Measurement ofACTH secretion
Duplicate 50pl aliquots of experimental medium was assayed for immunoreactive
ACTH using a double antibody precipitation radioimmunoassay (Dayanithi &
Antoni, 1989) after appropriate dilution in RLA buffer [0.05M sodium phosphate
buffer, pH7.4, 0.1% BSA, 0.1% Triton-X-100, 2.5mM EDTA and 100 kallikrein
inhibitor units (KIU) of aprotinin per ml].
Fifty microlitres of sheep ACTH antiserum (courtesy of Prof P.J. Lowry, University
of Reading) at a final titre of 1:100,000 in RIA buffer containing 6% polyethylene
glycol 6000 (PEG-6000), were mixed with 50pl of sample in a polypropylene
microtiter RIA vial (Sarstedt, Sevelen, Switzerland). The assay mix was incubated
with lOpl of 125I-ACTH (typically between 12,000 to 15,000 cpm in 10pl sodium
phosphate buffer without PEG-6000) for 18 h at 4°C. Subsequently, donkey anti-
sheep IgG (Scottish Antibody Production Unit, SAPU, Lanarkshire) and non-
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immune rabbit serum (SAPU) were added to a final titre of 1:25 and 1:400
respectively and incubated for 3 h at 4°C. Four hundred microlitres of ice-cold 6%
PEG-6000 were added and the bound label separated from free by centrifugation at
l,950g for 25 min at 4°C. The resultant supernatant was decanted, tubes washed and
blot-dried, and the radioactivity remaining in the pellet counted on a Packard
autogamma counter.
Standard curves were constructed in the range 0.125 to 32.0 fmol ACTH/50pl using
human ACTH1.39 diluted in DMEM or RIA buffer as appropriate. Non-specific
binding was determined by either incubating in the presence of excess unlabelled
ACTH or by omitting the ACTH antiserum and was typically <10% of the total
bound counts. Inter- and intra-assay coefficients of variance were typically <10%
and <5% respectively.
ACTH content was determined by interpolation from the % Bound counts vs log
ACTH concentration curve (see Figure 2.2), or its logit transformation, generated
using the respective algorithm of the Packard Cobra autogamma analysis package.
Specific bound counts were typically 35% of total counts applied. Percent bound















Figure 2.2: ACTH concentration standard curve using sheep anti-ACTH at a final
dilution of 1:100,000, generated using the RIA method described in section 2.3.1.
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Where X= cpm for standard/unknown sample, B0 = cpm in the absence of ACTH
and NSB is the non-specific cpm.
Logit %B is defined as:
i %B
1QS i00-%5
2.4 cAMP accumulation experiments
Cells used for cAMP accumulation experiments were prepared similarly as described
for ACTH secretion experiments (section 2.2 and 2.3). Prior to experimental
manipulation, cells were washed twice and maintained in DMEM (see section 2.3)
for 1 h at 37°C after which drugs were introduced for 30 min before fresh drugs and
secretagogues were applied for various lengths of time at 37°C. cAMP production
was terminated by addition of HC1 to a final concentration of 0.1M. Total cellular
cAMP was extracted by one cycle of freeze-thawing in 0.1M HC1 and determined by
radioimmunoassay.
2.4.1 Measurement ofcAMP accumulation
Duplicate 50pl samples of cell extract in 0.1M HC1 were assayed for
immunoreactive cAMP using a double antibody precipitation reaction (Dufau et al.,
1973) using cAMP antiserum, Cab4 (courtesy of Dr KJ Catt, NIH, Bethesda, USA)
at a final dilution of 1:100,000. All assay reactions were performed in polypropylene
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tubes (Alpha-Labs) in 50mM sodium acetate buffer, pH6.0 containing 0.25% BSA
and 10% sodium azide. Samples were incubated overnight at 4°C with AL43,
typically between 12,000 and 15,000 cpm of l25I-cAMP, donkey anti-rabbit IgG
(1:30 final dilution, SAPU) and non-immune rabbit serum (1:200 final dilution,
SAPU). Subsequently, 700pl of ice-cold 6% PEG-6000 was added and the bound
label separated from free by centrifugation at l,950g for 25 min at 4°C. Non-specific
binding was typically <10% of total bound counts, approximately 40% of total
counts bound to the antiserum. Inter- and intra-assay coefficients of variance were
typically <10% and <5% respectively. Standard curves were generated in the the
range 0.78 to 400 frnol cAMP/50pl using cAMP (Sigma) as standard. Assayed




2.5 Generalmolecular biology methods
All routine molecular biology techniques such as restriction digestion, gel
electrophoresis, cloning etc. were performed as described in (Sambrook et al., 1989).
2.5.1 Total RNA extraction
Total RNA was extracted using TRIZOL® Reagent (GibcoBRL), a mono-phasic
solution of phenol and guanidine isothiocyanate, based on the single-step
guanidinium thiocyanate-phenol-chloroform RNA isolation method. Approximately
107 AtT20 cells (70-80% confluency) were lysed directly as a monolayer from a
75cm2 flask using 5ml of the TRIZOL® Reagent and homogenised by trituration in a
sterile polypropylene tube (Falcon). After 5 min incubation at room temperature to
permit the complete dissociation of nucleoprotein complexes, 1 ml of chloroform
was added and shaken vigorously for 15 seconds before incubation at room
temperature for a further 3 min. Samples were centrifugated at 12,000g for 15 min at
4°C and the aqueous phase from the resultant supernatant was transferred to a fresh
tube to which 2.5ml of the isopropanol was added and incubated at room temperature
for 10 min. After centrifugation at 12,000g for lOmin at 4°C, the RNA pellet was
washed in 75% ethanol (made up in sterile diethylpyrocarbonate (DEPC)-treated
water) and recentrifuged at 12,000g for 5min at 4°C. The resulting RNA pellet was
dried and resuspended in 50pl of DEPC-treated water. RNA quality and quantity
was determined using the absorbance ratio at 260 and 280nm and by ethidium
bromide staining of agarose gels.
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2.5.2 Random prime labelling ofcDNA inserts
cDNA inserts were cut overnight from vector DNA using the appropriate restriction
enzymes (Sambrook et al, 1989) and gel purified on a 0.7% low-melting point
agarose (GibcoBRL) gel run in IX TAE (40mM Tris, 20 mM acetic acid, ImM
EDTA, pH 8.0) buffer. The excised insert was heated at 100°C in lOOpl of UEIP
(Ultra High Purity) water until the gel just melted and subsequently used for
labelling reaction using the Ready-to-Go® DNA labelling kit (Pharmacia). For the
labelling reaction, sixty-five nanograms (determined by spectrophotometry at
OD260nm) of heat denatured DNA insert was used as template in a reaction volume of
50pl containing the reconstituted Reaction Mix from the Ready-to-Go® kit and
50pCi a32P-dCTP (DuPont). The reaction was carried out at 37°C for 30 min and
terminated by the addition of 50pl of stop solution (40mM EDTA). Labelled DNA
was purified by Sephadex G-25 column chromatography (Nu-Clean, IBI Ltd,
Cambridge, UK) according to the manufacturer's instruction and used directly in
hybridization. DNA was typically labelled to a specific activity of >1x109 cpm/pg.
2.5.3 Northern blottins and hybridization
Total RNA was denatured for 15 min at 65°C in MOPS/EDTA buffer (20mM
MOPS, pH 7.0 (3-(N-morpholino)propanesulfonic acid) containing 0.66M
formaldehyde, 5mM sodium acetate and ImM EDTA). Samples were
electrophoresed for 3 h at 90V on a 1% agarose gel (GibcoBRL) containing 0.66M
formaldehyde using MOPS/EDTA as running buffer (Founey et al,1987). After
equilibrating the gel in 10X SSC (1XSSC : 150mM NaCl, 15mM trisodium citrate,
pH7.0) for 5 min, RNA was transferred overnight at 4°C by capillary blotting to
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nitrocellulose (Schleicher & Schull, Dassel, West Germany) using 10X SSC.
Subsequently, RNA was fixed onto nitrocellulose membrane by baking for 2 h at
80°C before use in hybridization.
Northern blots were typically prehybridized for 2 h at 55°C in 50% v/v deionized
formamide (Sigma), 5X SSC, 2X Denhardts (Sigma), 0.1% w/v SDS and 0.2mg/ml
salmon sperm carrier DNA (Sigma). Labelled DNA was applied directly to the
prehybridization mixture (typically 2xl06 cpm/ml) and incubated at 50°C for 16-18h
in a hybridization chamber. Filters were washed twice with IX SSC, 0.1% SDS at
50°C for 15min and then with 0.1X SSC, 0.1% SDS for a further 15 min.
Subsequently, filters were exposed at -70°C to Kodak Hypermax beta film using
intensifying screens for 3 days before autoradiographs were developed.
2.5.4 Transformation ofcompetent E.Coli cells
Competent bacteria cells were generated using the CaCh method (Sambrook et al.,
1989). Fifty millilitres of pre-equilibrated LB-broth were inoculated with 0.5ml of
an overnight 50ml culture of bacteria (JM-109) and incubated at 37°C with shaking
to an OD600 of 0.2. Flasks were cooled on ice and bacteria pelleted at 2,500g for 5
min at 4°C. The pellet was resuspended in 25ml of ice cold 50mM CaCl2 and
incubated at 4°C for 4 h and subsequently used for transformation with plasmid
DNA. Typically, 20ng of plasmid DNA was incubated for 30 min on ice with 200jlx1
of competent bacterial cells, followed by heat shock treatment for 2 min at 42°C,





Minipreps of plasmid DNA were prepared from 3 ml overnight bacterial cultures in
LB-broth (lOg Bacto-tryptone, 5g Bacto-yeast extract, lOg NaCl per litre) containing
50pg/ml ampicillin using the Akaline Lysis method (Sambrook et al., 1989).
Cultures were pelleted and resuspended in lOOpl of ice-cold solution 1 (50mM
glucose, 25mM Tris pH 8.0, lOmM EDTA), followed by addition of 200pl of
solution 2 (0.2M NaOH, 1% SDS) to lyse the cells and 150pl of solution 3 (3M
potassium, 5M acetate). Cell debris was pelleted at 12,000g at RT for 5 min and
nucleic acids were separated from proteins by applying 450pl of phenol/chloroform
and centrifugation (12,000g, RT, 2 min). DNA was precipitated from the resultant
supernatant (aqueous phase) with an equal volume of isopropanol followed by
centrifugation at 12,000g for 5 min at RT. The DNA pellet was washed with 75%
ethanol, dried and resuspended in 50pl of sterile UHP water containing 20pg/ml
RNase A and stored at -40°C.
2.5.6 Generation ofuni-directional cDNA inserts
The uneven termini of double stranded cDNA were blunted using 9U ofKlenow in a
40pl reaction mix containing 0.5M Tris-HCl, pH7.6, 0.1M MgC12 and 25pM each of
dATP, dCTP, dGTP and dTTP at 37°C for 15 min. The blunted cDNA inserts were
extracted using the Geneclean® II kit and restriction digested with Xba I. This
generates cDNA with a 5' blunt end and a 3' Xba I recognition site that allows uni¬
directional insertion of the cDNA into the pcDNA3 vector.
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2.5.7 Ligation ofcDNA into ylasmid vectors
Typically, 0.5pg of cDNA was ligated to lOpg of calf intestinal alkaline
phosphatase-treated pcDNA3 or pUHC10-3 vectors to achieve optimum ligation.
Ligation was carried out in a 20pl reaction containing: lOmM Tris-acetate, lOmM
magnesium acetate, 50mM potassium acetate, ImM ATP and 9 Weiss units of T4
DNA ligase, for 16 to 18 h at room temperature. Ligation reactions (IOjlxI) were used
to transform competent JM-109 (see section 2.5.4).
2.6 Generation of constitutive and inducible calmodulin over-expression
systems in AtT20 cells
A schematic outline of the methodology for generating stable AtT20 cell lines that
constitutively overexpress calmodulin (CaM) or contain inducible calmodulin over-
expressing constructs in shown in Figure 2.3.
For the constitutive over-expression system, wild type or mutant [CaM-8, 8 amino
acids deleted and therefore has lost its ability to activate its downstream targets, but
9+
can still bind Ca ; (Ribar et al., 1995)] chicken CaM cDNA fragment was subcloned
into pcDNA3 (a mammalian expression vector from Invitrogen). Recombinant
CaM-containing pcDNA3 constructs were transfected into AtT20 cells by
electroporation. Transfected AtT20 cells were selected with 0.6mg/ml geneticin
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(G418, GibcoBRL) for typically about 10 to 12 weeks before stablly transfected
AtT20 cell lines were obtained.
For the inducible expression system, the same wild type or mutant CaM cDNA
fragments used in the constitutive over-expression system, were subcloned into the
pUHC10-3 vector, part of the reverse tetracycline (rTet) inducible expression system
(Gossen et al., 1995). AtT20 cells were first transfected with the vector containing
the rTet transcription activator moiety pUHD17-3) and selected with 0.6mg/ml
G418. Subsequently, the CaM-containing puHC10-3 vector (obtained by ligation,
see section 2.5.7) was co-transfected with a puromycin-resistant vector into AtT20
cells already stably transfected with pUHD17-3. These AtT20 cells were selected
with both puromycin and G418 to ensure that both the pUHC10-3 (which contains
the CaM cDNA fragment) and pUHD17-3 vectors (which contains the rTet moiety)
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Figure 2.3: See section 2.6 for full description of the methodology of creating these





2.7.1a Preparation of cell extracts
Stably transfected AtT20 cells were stripped and pelleted in HBSS at 200g for 5 min
at 4°C. Cell pellets were resuspended in homogenisation buffer containing 20mM
Tris-HCl, pH7.5, ImM EGTA, 200 KlU/ml aprotinin and 2mM
phenylmethylsulfonyl fluoride (1.5-2 X 107 cells/ml) and lysed by one cycle of
freeze-thawing in liquid nitrogen and 30°C water bath. The homogenate was
centrifuged at 2,000g for 10 min, followed at 30,000g for 20 min at 4°C. Any
intrinsic cyclic nucleotide phosphodiesterase (PDE) activity was eliminated by heat
inactivating the supernatant at 95°C for 5 min, followed by centrifugation at 30,000g
for 20 min at 4°C to yield the cytosolic fraction. The amount of protein was
quantitated using Coomassie Protein Assay Reagent (Pierce, Chester, UK) with BSA
as standard based on the method of (Bradford, 1976).
2.7.1b Calmodulin assay
Calmodulin content was measured by minor modifications of a radiometric assay
(Schilling, 1994) for quantitating PDE activity based on the precipitation of cAMP
hydrolysis product, 5'-AMP, with ZnS04-Ba(0El)2 treatment (Krishna, 1968). The
PDE assay buffer contained lOOmM Tris-HCl, pH7.5, 5mM MgS04, 0.2mM Ca2+,
10pl of cell extract (approximately 10pg protein, Section 2.6.1a) and 0.2U/ml of
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bovine brain PDE (Sigma), in a total volume of 150pl. After preincubation at 30°C
for 10 min, the reaction was initiated by the addition of 50pl substrate (containing a
final concentration of 100pM cAMP and 0.2pCi/ml [2,8-3H]cAMP) and incubated at
30°C for 15 min. The reaction was terminated by the addition of lOOpl of 21.5mM
ZnSC>4 followed by lOOpl of 17.5mM Ba(OH)2 to precipitate the 5'-AMP formed.
The suspension was subsequently filtered over Whatman GF/C filters on a vacuum
manifold, and washed twice with 3ml of ImM NaOH/lOOmM NaCl. Radioactivity
retained on the filters was measured by liquid scintillation counting with 10ml of
Emulsifier-SAFE™ scintillation cocktail (Packard Bioscience, Pangbourne,
Berkshire, UK). Assays for background levels of calmodulin were carried out using
the homogenisation buffer (see section 2.7. la) in place of cell extracts.
2.7.2 Analysis ofresults
Each experiment was carried out at least twice with n replicates for each treatment
within each experiment. All data are presented as means±SEM and were analyzed
by 2- or 1-way analysis of variance followed by Dunnett's test, Newman Keuls' test
or contrast of means where appropriate. Results presented as percentage of control
ACTH release were derived from the raw data as follows: (X-B)/(C-B) X 100%,
where B refers to the basal ACTH secretion, C refers to ACTH secretion elicited by
the control stimulus and X refers to ACTH secretion elicited by the control stimulus
in the presence of dexamethasone or corticosterone.
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RELEASE IN AtT20 CELLS
Introduction
Early (<2h) glucocorticoid inhibition of stimulated ACTH release in anterior
pituitary corticotrophs involves the rapid induction of new mRNA and proteins
(Arimura et al., 1969; Brattin & Portanova, 1977; Dayanithi & Antoni, 1989; Woods
9-4-
et al., 1992) that suppress intracellular free Ca transients (Antoni et al., 1992).
Previous studies in AtT20 cells have demonstrated that the synthetic glucocorticoid
dexamethasone significantly raised the levels of steady state calmodulin mRNA by
90 min after application of the steroid to AtT20 cells (Shipston & Antoni, 1992).
This suggested that calmodulin may be one of the proteins newly induced by
glucocorticoids. Therefore, this section of the thesis serves to verify the putative role
of calmodulin as a mediator of early glucocorticoid feedback inhibition in AtT20
cells and attempts to define the mechanisms of calmodulin action. For instance, is
9+ 9-1-
calmodulin acting as a Ca buffer to disrupt Ca homeostasis or is the effect of
calmodulin exerted through Ca2+/calmodulin activated enzymes. To address this,
AtT20 cells constitutively over-expressing calmodulin or a mutant form of
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calmodulin (CaM-8) that only displays Ca2+ binding (see section 2.6 for the
methodology of creating these novel AtT20 cell lines) were generated. The cell lines
that stably over-expressed calmodulin were then analyzed for their ability to mimic
the inhibitory effect of glucocorticoid on stimulated ACTH secretion by studying the
characteristics of basal and CRF-stimulated ACTH secretion in these novel




3.2 Characterisation of calmodulin over-expression in calmodulin-
transfected AtT20 cells
3.2.1 Northern analysis ofcalmodulin mRNA in stably transfectedAtT20 cells
AtT20 cells stably transfected with recombinant mammalian expression vector
pcDNA3 containing calmodulin or CaM-8 were characterised initially by analysis of
mRNA expression. Figure 3.1 shows the different amounts of a ~1.6kb mRNA
species that hybridized to a chicken calmodulin probe. Of the calmodulin-
transfected AtT20 cell lines, CaM2 (Figure 3.1) showed the strongest hybridization
signal at ~1.6kb, indicating the constitutive expression of elevated calmodulin
mRNA. The hybridization signal was weak in wild type AtT20 cells (Figure 3.1)
because endogenous calmodulin mRNA is low. Moreover, the chicken calmodulin
probe does not cross react with endogenous mouse calmodulin mRNA under the high
stringency conditions used for the hybridization (see section 2.5.3).
3.2.2 Measurement offunctional calmodulin levels in transfectedAtT20 cells
The amount of functional calmodulin protein was assessed by measuring the activity
2_|_ #of a Ca /calmodulin activated cyclic nucleotide phosphodiesterase (PDE) (described
in section 2.7.1b). The transfected AtT20 cell line (CaM2, see Figure 3.1) in which
apparently elevated levels of calmodulin mRNA were detected, the functional
calmodulin levels were significantly higher than in wild type AtT20 cells, control
pcDNA3-transfected and mutant CaM-8 transfected AtT20 cell lines (Figure 3.2).
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The calmodulin levels measured in CaM2 were 302±32% of that measured in wild
type AtT20 cells (designated 100%)(mean of 3 experiments, n=3, p<0.05 when
compared to wild type AtT20 cells, Student's 2-tailed, unpaired t-test).
The analysis of calmodulin mRNA and protein levels in CaM2 has indicated that this
transfected AtT20 cell line is constitutively over-expressing functional calmodulin




Characterisation ofcalmodulin mRNA expression in wild type and
stably transfectedAtT20 cells





Figure 3.1: (a) Northern blot for calmodulin mRNA in duplicate lanes for: (1) AtT20
cells transfected with recombinant mammalian expression vector pcDNA3
containing mutant calmodulin (CaM-8) cDNA; (2), (3) and (4) different clones of
AtT20 cells transfected with recombinant pcDNA3 containing chicken calmodulin
cDNA; (5) AtT20 cells transfected with pcDNA3 alone and (6) wild type AtT20
cells. NB: (4) is designated CaM2 for further reference. Total RNA for each cell
line was run in duplicate lanes and hybridised with a (a32P) dCTP labelled 0.28kbp
Hindlll fragment of chicken calmodulin cDNA (pGMCaMc). Blots were hybridised
as described in section 2.5.3, autoradiographs were exposed for 3 days, (b) Ethidium
bromide-stained gel electrophoresis of total RNA (20pg/lane) of the corresponding




Characterisation offunctional calmodulin protein levels in wild type












AtT20 pcDNA3 CaM2 CaM-8
Figure 3.2: Amounts of calmodulin measured in wild type AtT20 cells (AtT20),
AtT20 cells transfected with a mammalian expression vector pcDNA3 (pcDNA3),
with recombinant pcDNA3 containing calmodulin cDNA (CaM2) or containing a
mutant calmodulin cDNA (CaM-8). Solid columns are means, bars indicate SEM,
n=3/group. The functional calmodulin levels were measured with a Ca2+/calmodulin-
activated PDE assay (described in section 2.7.1b) and standardised to cytosolic
protein content (defined in section 2.7.1a). *P<0.01 when compared to calmodulin
level measured in AtT20, 1 -way ANOVA followed by Newman-Keuls test. Where
error bars are not visible, the SEM bars are too small to be seen on this scale.
Results shown are representative of 3 measurements.
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3.3 Characteristion of CRF-stimulated ACTH release in stably
transfected AtT20 cells
In order to investigate whether the constitutive over-expression of calmodulin in
AtT20 cells could mimic the early onset inhibition of stimulated ACTH release by
glucocorticoid, ACTH release by CaM2 in static incubation studies were carried out.
3.3.1 Response to CRF
The variation of the absolute amounts ofACTH release by wild type and transfected
AtT20 cells precluded direct statistical comparison (see figure legend of Figure 3.3
for the absolute basal values in fmol/well). Therefore, lOnM CRF-stimulated ACTH
release from wild type and transfected cells was expressed as percentages of basal
ACTH release within each cell type. The ACTH response to lOnM CRF was not
significantly different among wild type AtT20, control pcDNA3-transfected AtT20
and CaM2 cells (Figure 3.3).
In summary, the data above show that the apparent constitutive expression of
elevated calmodulin levels in the calmodulin over-expressing AtT20 cell line CaM2,
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Figure 3.3: ACTH release elicited by lOnM CRF in wild type AtT20 cells (AtT20),
AtT20 cells transfected with pcDNA3 and with recombinant pcDNA3 containing
calmodulin cDNA (CaM2). Solid columns are means, bars indicate SEM, n=3-
4/group and expressed as % of lOnM CRF-induced ACTH release over basal release
within each of the respective cell lines. Basal release in fmol/well (means±SEM)
from AtT20, pcDNA3 and CaM2 cell lines respectively — Expt 1: 417.0±13.8,
424.8±35.1, 573.6±5.8 ; Expt 2: 764.3±69.0, 628.7+35.8, 1045.1±41.5 ; Expt 3:




3.4 Preliminary study of an inducible expression system in AtT20 cells
Results from section 3.3.1 indicated that constitutive over-expression of calmodulin
appears to have no discernible effect on CRF-induced ACTH release in AtT20 cells.
Instead, an inducible expression system may be more appropriate for mimicking the
induction of new proteins by glucocorticoids during the early onset of feedback
inhibition. To address this issue, the reverse tetracycline repressor (rTet) -regulated
inducible expression system developed by Gossen and colleagues (Gossen et al.,
1995) was tested for its suitability for use in AtT20 cells. As the tetracycline
derivative doxycycline was a more potent agent for inducing gene expression in this
Tet system, its effects on ACTH secretion were examined in normal AtT20 cells.
3.4.1 Doxvcvcline reduced CRF-stimulatedACTH release
An optimal concentration of doxycycline (1 pg/ml), based on previous studies by
Gossen and colleagues (Gossen & Bujard, 1992), was used to treat ATt20 cells for
30 min or 5 h. CRF (lOnM) was applied to stimulate ACTH secretion after the
various lengths of doxycycline treatment. Doxycycline (1 pg/ml) had no effect on
basal ACTH release but significantly reduced the ACTH response to lOnM CRF
(Figure 3.4).
These results suggested that the use of the Tet inducible expression system in AtT20














Length of doxycycline induction (h)
Figure 3.4: Effect of l(ig/ml doxycycline on the ACTH secretory response elicited
by lOnM CRF. AtT20 cells were treated with doxycycline for the specified length of
time before the cells were challenged with lOnM CRF or vehicle. Cells that received
no doxycycline treatment were incubated with vehicle solution for 5 h before
stimulation with lOnM CRF or vehicle. Data represent means±SEM, n=4/group.
*P<0.05 when compared to control (i.e. no doxycycline treatment). Where error bars
are not visible, the SEM bar is less than the space required for the symbol. Results




The data presented in this section show the elevation of calmodulin mRNA and
functional protein levels in AtT20 cells that have been stably transfected with a
recombinant mammalian expression vector (pcDNA3) containing a chicken
calmodulin cDNA. However, CRF-stimulated ACTH secretion by these cells were
apparently unchanged as compared to the secretion elicited by wild type AtT20 cells.
This suggests that the constitutive over-expression system may not be the most
appropriate system to address the issue of whether calmodulin may mediate early
glucocorticoid feedback inhibition in AtT20 cells.
3.5.1 Evaluation ofthe constitutive calmodulin over-expressinsAtT20 system
Calmodulin is a ubiquitous calcium-binding protein that has been shown to have
wide ranging effects on physiological processes including cell growth, secretion and
cell motility (Agell et al., 1998; Hartwig et al., 1992; Means et al., 1991; Pritchard &
Moody, 1986; Schulman, 1993). With regard to cell growth, it has been shown using
anti-calmodulin drugs and genetic manipulation of calmodulin genes that calmodulin
plays an important part in the regulation of nuclear functions like DNA synthesis and
the onset and progression ofmitosis cf (Bachs et al., 1994). Given that calmodulin
takes part in such fundamental processes required for maintaining cell viability, it
seems likely that the level of biologically active calmodulin would be tightly
regulated in the cell. In fact, it has been reported that over-expression of normal
calmodulin led to cardiomyocyte hypertrophy in transgenic mice (Gruver et al.,
1993). Hence, one reason why elevated amounts of calmodulin mRNA and protein
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could not be detected in most of the stably transfected calmodulin over-expressing
AtT20 cell lines, may in part relate to the downregulation of the excess proteins
[through ubiquitylation cf (Jennissen, 1995)] produced in these transfected AtT20
cell lines. Furthermore, recent studies have demonstrated that the reversible
ubiquitylation of calmodulin by ubiquityl-calmodulin synthetase in the presence of
Ca2+ strongly decreased the biological activity of calmodulin towards phosphorylase
kinase (Laub & Jennissen, 1997; Laub & Jennissen, 1991). Therefore, although the
excess calmodulin expressed in the transfected cell lines is not channeled to
degradation by the 26S proteasome upon ubiquitylation (Varshavsky, 1997), its
biological activity may be markedly reduced (Laub et al., 1998).
Thus, from a physiological viewpoint, an inducible system that can be regulated to
transiently overexpress calmodulin would be more favourable. Furthermore, such a
system would simulate the early onset inhibition of glucocorticoid more accurately
since de novo synthesis of mRNAs and proteins occur within the time scale (i.e.
within 2h) of early onset glucocorticoid inhibition.
3.5.2 Inducible expression systems for over-expressins calmodulin in AtT20 cells
The artificial transcriptional regulatory system that uses the bacterial tetracycline
operator/repressor first described by Gossen and Bujard (Gossen et al., 1995) seems
a suitable system to use. In particular, the rTet system which can drive the
expression of calmodulin in AtT20 cells in response to varying concentrations of
tetracycline or its derivative doxycycline would suit the purpose of mimicking
glucocorticoid induction of new proteins well. In the initial attempts to assess the
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feasibility of this inducible rTet system, the effect of doxycycline on ACTH
secretion by wild type AtT20 cells was examined. Doxycycline was used because it
was reportedly more potent (about 5-fold more than tetracycline) in driving gene
expression in the rTet system.
Analysis of the characterisitics ofACTH secretion by AtT20 cells in the presence of
doxycycline revealed that while basal secretion was not significantly modified, CRF-
elicited secretion was significantly reduced when cells were treated with doxycycline
for 30 min or 5 h (Figure 3.4). The duration of induction with doxycycline between
30 min and 5 h would most probably be appropriate for simulating the time scale for
onset of early glucocorticoid inhibition. Therefore, any potential effect that the
newly induced calmodulin may have on CRF-stimulated ACTH secretion will be
masked by the inhibitory effect that doxycycline appears to exert on secretion. It is
not clear why doxycycline inhibits ACTH secretion. One reason might be because
2"F •Ca has been reported to be important for the transport of tetracyclines (including
doxycycline) in blood plasma (Berthon et al., 1983; Jun & Lee, 1980; Lambs et al.,
1984). Hence, doxycycline may act as a calcium chelator and interfere with ACTH
• t |
secretion which requires intracellular free Ca . The tetracycline-regulated inducible
expression system is thus not appropriate for addressing the role of calmodulin in
early glucocorticoid inhibition of ACTH secretion by adenohypophysial
corticotrophs.
Interestingly, a recent study (Schiller et al., 1997) reported the use of AtT20 cells
engineered to inducibly express the regulated endocrine-specific protein (RESP18)
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using the same rTet inducible expression system. This inducible system appeared to
work well for their study since they were able to demonstrate the existence of a novel
signalling pathway from the secretory pathway lumen to the nucleus, using this
system.
Other mammalian inducible expression systems have since become commercially
available. Of note is the ecdysone-inducible expression system from Invitrogen,
which drives gene expression with the analogues of an insect steroid hormone
ecdysone. As Ponasterone A and Muristerone A (the ecdysone analogues) are
reportedly inert to mammalian physiology, the ecdysone-inducible system may be
useful for driving the transient over-expression of calmodulin in AtT20 cells and will
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INVESTIGATION OF THE MECHANISMS
OF EARLYGLUCOCORTICOID
INHIBITION IN RAT ANTERIOR
PITUITARY PRIMARY CULTURES
4.1 Maintenance of the membrane potential in early
glucocorticoid inhibition in corticotrophs
4.1.1 Introduction
CRF-stimulated ACTH release is mediated through cAMP-activated protein kinase
enhancement of Ca2+ influx through voltage-gated Ca2+-channels in the AtT20
mouse corticotroph tumour cell line (Luini et al., 1985; Reisine et al., 1986; Reisine
et al., 1985; Richardson, 1986). BK-channels, previously identified in AtT20 cells
(Wong et al., 1982), have been proposed as important negative feedback regulators
of voltage-dependent Ca2+ influx (Twitchell et al., 1997), thus important for restoring
cellular excitability. Studies in AtT20 cells have shown that membrane
depolarization antagonised glucocorticoid inhibition of stimulated ACTH release
(Phillips & Tashjian Jr, 1982; Woods et al., 1994). In addition, Ca2+-channel
activators (Antoni et al., 1992; Pennington et al., 1994) and K+-channels inhibitors
(Pennington et al., 1994; Woods et al., 1994), including BK-channel inhibitors
(Shipston et al., 1996), have also been demonstrated to antagonise glucocorticoid
inhibition in AtT20 cells. These studies collectively indicated that early
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glucocorticoid feedback inhibition targets the membrane potential in AtT20 cells.
Hence, the objective of this section of the thesis was to investigate the importance of
the maintenance of membrane potential in glucocorticoid inhibition of stimulated
ACTH release in normal rat anterior pituitary corticotrophs. Furthermore,
pharmacological tools were used in an effort to identify the underlying K+-channels
that may be involved in glucocorticoid inhibition of stimulated ACTH release. CRF
at physiological concentrations and a membrane-permeant, non-metabolisable cAMP
analogue, 8-(4-chlorophenylthio)adenosine-3',5'-cyclic-monophosphate (CPT-
cAMP) were used as the primary secretagogue stimulus. CPT-cAMP mimics the
increase in intracellular cAMP levels caused by CRF, but is not subject to the
94-
complex Ca -dependent regulation of cAMP metabolism that is evident in
corticotroph cells.






4.1.2 Eliciting membrane depolarization with common K -channel
2+
blockers and Ca -channel activators
Experiments with AtT20 cells
4.1.2a Resvonse to CPT-cAMP and dexamethasone
Concentration-dependent stimulation of ACTH release was evoked by CPT-cAMP
(Figure 4.1) and the response plateaued at ImM CPT-cAMP. Pretreatment for 2h
with lOOnM dexamethasone significantly reduced the increase in CPT-cAMP -
stimulated ACTH secretion, basal hormone output remained unaltered (Figure 4.1).
4.1.2b Effects ofTEA and (~)BayK8644
The ACTH response to ImM CPT-cAMP could be enhanced further by the
application of 5mM tetraethylammonium (TEA, a broad spectrum K+-channel
blocker) or the Ca2+-channel activator (-)BayK8644 at 5pM (Figure 4.2a). Both of
these compounds stimulated ACTH release when given alone and exhibited
synergistic interaction with CPT-cAMP. Similar data were obtained with another L-
channel activator (+)202-791 at 5pM (not shown).
The release of ACTH evoked by ImM CPT-cAMP was inhibited by 65.8±8.9%
(n=5) by lOOnM dexamethasone, while basal secretion was not significantly altered




Concentration dependent increase ofACTH secretory response to
CPT-cAMP in AtT20 cells
ACTH (fmol/well)
CPT-cAMP (mM)
Figure 4.1: The effect of CPT-cAMP on ACTH secretion by AtT20 cells pretreated
for 2h with vehicle (empty circles,) or lOOnM dexamethasone {filled circles). Means,
the bars indicate SEM, n=5/group. Where error bars are not visible, the SEM bar is
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ImM CPT-cAMP and 5mM TEA or ImM CPT-cAMP and 5pM (-)BayK8644 was
significantly attenuated to 30.7±11.8% and 31.9±7.6% (p<0.05, n=5), respectively
(Figure 4.2a & b). The combination of ImM CPT-cAMP with 5pM (+)202-791 also
significantly reduced the inhibition of the stimulated ACTH secretion by lOOnM
dexamethasone to 27±1.3% (p<0.05, n=4/group, 1-way-ANOVA, Dunnett's test).
As both (-)BayK8644 and TEA partially reversed dexamethasone inhibition of CPT-
cAMP stimulated ACTH secretion, the combination of these compounds with CPT-
cAMP was tested subsequently, using a submaximal concentration (O.lmM) ofCPT-
cAMP as well as ImM CPT-cAMP. The ACTH secretion elicited by O.lmM CPT-
cAMP was significantly potentiated by 5pM (-)BayK8644 and 5mM TEA given
together (Table 4.1). CPT-cAMP-induced ACTH secretion was inhibited by
dexamethasone (InM to lpM) in a concentration dependent manner by up to 84%
(Table 4.1). The combination of 5pM (-)BayK8644 and 5mM TEA elicited a 3-fold
increase in ACTH secretion over basal levels and this response was not inhibited by
dexamethasone (Table 4.1). The ACTH response elicited by the combination of
O.lmM CPT-cAMP, 5pM (-)BayK8644 and 5mM TEA was also fully resistant to
inhibition by 1-1000 nM dexamethasone (Table 4.1).
Similar results were obtained by combining ImM CPT-cAMP with 5mM TEA and
5pM (-)BayK8644. A summary of these data (Figure 4.3) shows that the extent of
resistance to glucocorticoid inhibition was independent of the amplitude of stimulus-
evoked ACTH secretion. For instance, although the ACTH release elicited by 5mM
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Figure 4.3
Size of the ACTH secretory response failed to predict the degree of
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Figure 4.3: Data were plotted as stimulus strength vs. % inhibition of ACTH
release, where stimulus strength is the size of the evoked release of ACTH expressed
as % of the response to ImM CPT-cAMP run in the same experiment, and %
inhibition of ACTH release is the degree of inhibition of the ACTH response to the
respective stimulus in cells preincubated with lOOnM dexamethasone, expressed as
percentage of the control (i.e. no dexamethasone) response (see section 2.3.1). Data
are means n=4/group. Symbols: CPT—ImM CPT-cAMP; BayK—5pM (-)
BayK8644; TEA—5mM tetraethylammonium; BayK/TEA — combination of 5pM
(-)BayK8644 and 5mM TEA; + sign indicates that two stimuli were applied together.
Results shown are representative of 2 experiments.
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TEA or ImM CPT-cAMP alone were similar, the ACTH response to 5mM TEA was
much more resistant to dexamethasone inhibition than the response to ImM CPT-
cAMP.
Taken together, these results are in agreement with previous studies of CRF-induced
ACTH release in AtT20 cells, which have shown that early glucocorticoid inhibition
is effectively counteracted by depolarization of the membrane potential (Woods et
al., 1994) and that TEA sensitive K+-channels underlie the inhibitory action of
corticosteroids (Shipston et al., 1996).
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Experiments with primary cultures of rat anterior pituitary
4.1.2c Response to CPT-cAMP
The time-course of the ACTH response to CPT-cAMP was close to linear over 4h
(Figure 4.4a). The concentration-response relationship between CPT-cAMP and
ACTH release was similar at 60,120 and 240 min, in that 0.1 mM CPT -cAMP
elicited close to maximal stimulation of ACTH release (Figure 4.4b). This was not
the case at 30 min, where ImM CPT-cAMP was significantly more effective than
O.lmM CPT-cAMP. All subsequent experiments were terminated at the 60 min time-
point.
4.1.2d Lack ofeffect ofTEA and (~)Ba\K8644 on glucocorticoid inhibition ofACTH release
Corticosterone (lOOnM) reduced the ACTH response to O.lmM CPT-cAMP by
74.8±10.8% (n=5) and this was not modified in the presence of TEA (5-20mM) or (-
)BayK8644 (5pM). Similar findings were obtained with 30nM dexamethasone.
Combination of 5mM TEA and (-)BayK8644 (5pM) produced a significant
enhancement of the ACTH releasing effect of CPT-cAMP (0.3mM) (in fmol/well—
Basal: 34±6; CPT-cAMP: 125±5; TEA+BayK: 60±6; CPT-cAMP+TEA+BayK:
204±14, n=5-7/group, p<0.05 for the interaction between CPT and TEA+BayK, 2-
way-ANOVA) but failed to modify the inhibition by lOOnM dexamethasone (%
inhibition ofCPT-cAMP vs CPT-cAMP+TEA+BayK: 63±7% vs 66±6%, n=4).
Qualitatively similar data were obtained using 0.1 nM CRF as the primary
secretagogue (summarized in Table 4.2). TEA (lOmM), (-)BayK8644 (5pM) or a
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combination of both drugs produced a synergistic enhancement of the ACTH
response to O.lnM CRF. Corticosterone (lOOnM) inhibition of O.lnM CRF-evoked
ACTH release was unaltered in the presence of lOmM TEA, (-)BayK8644 (5pM) or
a combination of both drugs (Table 4.2).
These data indicate that in contrast to AtT20 cells, TEA-sensitive ion-channels are
not fundamentally important for corticosteroid inhibition of ACTH secretion in
primary cultures of rat anterior pituitary cells.
4.1.2e Other common K -channel blockers also failed to modify corticosterone inhibition
2+Effects of apamin and 4-aminopyridine (4-AP), inhibitors of small conductance Ca -
activated K+-channels (SK-channels) and transient A-type K+-channels respectively,
on corticosterone inhibition were also investigated. CRF (O.lnM)-stimulated ACTH
release was not significantly modified by pretreatment with lOOnM apamin or ImM
4-AP (in fmol/well—Basal: 78.1±2.8; CRF: 182.2±16.3; CRF+apamin: 196.8±24.2;
CRF+4-AP: 212.0±11.5, n=4-6/group). Corticosterone (lOOnM) reduced O.lnM
CRF-induced ACTH response by 81.0±6.1% (n=6) and was not significantly
modified by lOOnM apamin or ImM 4-AP (% inhibition—CRF+apamin: 73.0+6.4,






















Figure 4.4: (a) Time-course of hormone release in cells treated with vehicle (filled
circles), 30pM CPT-cAMP (empty circles), O.lmM CPT-cAMP (filled diamonds) or
ImM CPT-cAMP (empty diamonds), (b) Concentration-dependent stimulation of
ACTH secretion by CPT-cAMP at 30min (empty triangles), 1 h (filled triangles), 2 h
(empty circles) and 4 h (filled circles) of incubation. Data are means±SEM,
n=4/group. Where error bars are not visible, the SEM bar is less than the space




Inhibition ofCRF-stimulatedACTHsecretion by corticosterone was






(100 ± 7.26 %)
66.73 ± 4.04
(33.48 ± 5.39 %)
TEA 37.95 ±2.62
BayK 40.28 ± 3.04
TEA+BayK 42.94 ± 2.03












Table 4.2: Effect of lOmM TEA and 5pM (-)BayK 8644 (BayK) on lOOnM
corticosterone (CORT) inhibition of O.lnM CRF-stimulated ACTH secretion. Data
show ACTH release expressed in fmol/well and represent means ± SEM
(n=4/group). Values in parentheses represent percentages of control ACTH release
(means±SEM, n=4/group), as defined in section 2.7.2. f p<0.05 for the interaction
between CRF and TEA, BayK or TEA/BayK in the absence of corticosterone
pretreatment, 2-way-ANOVA. Statistical analysis of the effect of CORT, carried out
on the data expressed as percentages (values in parentheses) of the respective
stimulus-evoked release, showed no statistical difference (1-way-ANOVA). Results
shown are representative of 2 experiments.
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4.1.3 Characteristics of CRF-stimulated ACTH release in the presence of
depolarizing concentration of KC1 in cultured rat anterior pituitary
cells
4.1.3a Depolarization with 40mM KCl counteracts glucocorticoid inhibition of ACTH
release
The ACTH responses to O.lmM CPT-cAMP and 40mM KCl are shown in Table 4.3.
KCl (40mM) synergised with O.lmM CPT-cAMP to stimulate ACTH release,
furthermore, it produced a marked reduction in the inhibitory effect of
dexamethasone (Table 4.3). Dexamethasone (lOnM) inhibited the ACTH response
to O.lmM CPT-cAMP and 40mM KCl by only 44±12% (n=4), while that evoked by
O.lmM CPT-cAMP was completely blocked. Similar results were also obtained
using the naturally occurring corticosteroid corticosterone (Table 4.3)
The ACTH responses to O.lnM CRF and 40mM KCl were also examined (Figure
4.5a). In contrast to the synergistic effects of combining O.lmM CPT-cAMP and
40mM KCl, the ACTH release elicited by the combination ofO.lnM CRF and 40mM
KCl was additive in 5 out of 7 experiments (synergism was observed only in 2
9+
experiments). Prevention of Ca entry by O.lmM cadmium completely blocked
ACTH release elicited by CRF alone or in combination with KCl (see Table 4.5).
Corticosterone (10-lOOOnM) inhibition of the ACTH response to O.lnM CRF and
40mM KCl was markedly reduced (Figure 4.5b).
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The data above demonstrate that depolarization of the membrane potential with KC1
markedly reduces the early inhibitory effect of glucocorticoids in normal rat
corticotrophs.
4.1.3b Blockers ofmRNA synthesis abolished early glucocorticoid inhibition
The inhibition of 0.1mM CPT-cAMP stimulated ACTH secretion by lOnM
dexamethasone was eliminated in the presence of 5,6-dichloro-furanosyl-
benzimidazole riboside (DRB), an adenosine analogue and inhibitor of heteronuclear
RNA synthesis (Egyhazi et al., 1982) (Figure 4.6a). In the presence of 40mM KC1,
DRB suppressed ACTH secretion elicited by 0.1mM CPT-cAMP but no further
change was observed after treatment with dexamethasone (Figure 4.6b). Therefore,
the residual inhibition by corticosteroids observed in the presence of 40mM KC1 and
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CPT+KC1 284.8±4.1 * 269.8±16.3 260.8±7.6 221.9±23.1 216.3±22.7






112.8±5.3 62.8±2.5 54.5±3.3 52.0±3.1
(100±11%) (~7±5%) (-25±7%) (-30±7%)
127.6±14.4
CPT+KC1 280.6±27.2 # 192.2±31.8 187.2±26.1 165.2±11.8
(100±13%) (59±15%) f (56±12%) t (46±6%) f
Table 4.3: Data show ACTH release expressed in fmol/well and represent
mean±SEM of 4 replicates per treatment group. Values in parentheses represent
percentages of control ACTH release (mean±SEM), as defined in section 2.7.2.
*p<0.0001 and #p<0.004 for the interaction between CPT-cAMP and KCl in the
absence of glucocorticoid pretreatment, 2-way ANOVA. Statistical analysis of the
effect of glucocorticoids was carried out on the data expressed as percentages (values
shown in the parentheses) of the respective stimulus-evoked release, fp<0-05 when
compared to the corresponding CPT group, 1-way ANOVA followed by contrast of
means. Results shown are representative of 2 and 3 experiments for the
corticosterone and dexamethasone dose responses respectively.
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Figure 4.6
Effect of the RNA synthesis inhibitor 5,6-dichloro-furanosyl-




























Figure 4.6: DRB (100|lM) and lOOnM dexamethasone (DEX) were applied 2h
before challenging the cells with (A) O.lmM CPT-cAMP or (B) O.lmM CPT-
cAMP and 40mM KCl for 60 min. Basal ACTH release was 44±3 fmol/well and
was not altered by DRB or dexamethasone. Columns are means, bars indicate SEM,
n=5/group. * P<0.05 when compared with control group receiving vehicle only. 1-




4.1.4 Role of BK-channels in glucocorticoid inhibition of stimulated
ACTH response
Experiments with AtT20 cells
4.1.4a Charybdotoxin reduced dexamethasone inhibition of CPT-cAMP-evoked ACTH
release
A potent inhibitor of BK-channels, charybdotoxin (ChTx), was used to verify the
involvement of BK-channels in the inhibitory action of glucocorticoid in AtT20
cells. Charybdotoxin (lOOnM) had no significant effect on the ACTH response
elicited by O.lmM CPT-cAMP (in fmol/well—Basal: 165 ± 9.8; CPT-cAMP: 507 ±
45.9; ChTx: 217 ± 19.7; CPT-cAMP+ChTx: 588 ± 65.0, n=4/group).
Dexamethasone (30nM) inhibition ofO.lmM CPT-cAMP elicited ACTH release was
markedly reduced in the presence of lOOnM charybdotoxin (% inhibition of CPT-
cAMP vs CPT-cAMP+ChTx: 98.1 ± 9.8% vs 49.5 ± 7.6%, n=4, p<0.05, Students
two-tailed, unpaired t-test).
These data are in agreement with results from a previous study (Shipston et al.,
1996) that dexamethasone inhibition of stimulated ACTH release are antagonised by
inhibitors of BK-channels in AtT20 cells. Therefore, BK-channels appear to play a
pivotal role in corticosteroid inhibition in AtT20 cells.
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Experiments with rat anterior pituitary primary cultures
4.1.4b Charybdotoxin failed to modify glucocorticoid, inhibition ofstimulatedACTH release
Table 4.4 summarizes the effect of lOOnM charybdotoxin on O.lmM CPT-cAMP and
0.1nM CRF elicited ACTH release in the absence and presence of lOOnM
corticosterone in normal rat corticotrophs. As was observed in AtT20 cells, the
ACTH response to O.lmM CPT-cAMP or O.lnM CRF was not significantly modified
by lOOnM charybdotoxin. Notably, the ACTH release elicited by the combination of
lOOnM charybdotoxin with O.lnM CRF or O.lmM CPT was inhibited by lOOnM
corticosterone to the same extent as in the absence of charybdotoxin (Table 4.4).
In sum, these data together with that in Section 4.1.2d suggest that BK-channels have
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Table 4.4: Effect of lOOnM charybdotoxin (ChTx) on lOOnM corticosterone
(CORT) inhibition of O.lmM CPT-cAMP (CPT) or O.lnM CRF-stimulated ACTH
release. Data show ACTH release expressed in fmol/well and represent means ±
SEM (n=4/group). Values in parentheses represent percentages of control ACTH
release (means±SEM, n=4/group), as defined in section 2.7.2. Statistical analysis of
the effect of CORT, carried out on the data expressed as percentages (values in
parentheses) of the respective stimulus-evoked release, showed no statistical
difference (1-way-ANOVA). Results shown are representative of 2 experiments.
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4.1.5 Analysis of the involvement of novel K -channels in corticosteroid
inhibition in rat anterior pituitary primary cultures
In order to probe further the K+-channels that may have a role in corticosteroid
inhibition, inhibitors of other less conventional K+-channels were tested for any
potential effect on corticosteroid inhibition. Recent molecular, pharmacological and
electrophysiological studies have revealed novel K+-channels responsible for the
repolarization of the cardiac action potential (Sanguinetti & Jurkiewicz, 1990).
These are the human ether-a-go-go related-gene (HERG)-channels and the
KvLQTl/IsK channels (see section 4.1.5c). The induction of similar channel
proteins have been linked to corticosteroids (Attali et al., 1995). In this study (Attali
et al., 1995), a K+-specific channel activity (which biophysical, pharmacological, and
regulatory characteristics are very similar to those reported before for IsK) was
expressed in Xenopus laevis oocytes. In rat GH3 anterior pituitary cells,
pharmacological and kinetic evidence has indicated that thyrotrophin-releasing
hormone regulates a HERG-like K+-current that is important for maintaining cellular
excitability in these cells (Barros et al., 1997). Furthermore, RT-PCR analysis has
revealed that mRNA of the rat homologue of HERG is present in GH3/B6 cells
(Bauer et al., 1998). It is therefore conceivable that HERG-type K+-channels may
also be expressed in rat adenohypophysial corticotrophs. Consequently, the effects
of clofilium (a KvLQTl/IsK-type K+-channel blocker,) and astemizole (an
antihistamine with anti-HERG-type K+-channel properties) on corticosteroid
inhibition of stimulated ACTH secretion were examined.
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4.1.5a Corticosterone inhibition ofCRF-induced ACTH response was reduced by clofilium
and astemizole
The effects of clofilium and astemizole on corticosterone inhibition of 0.1nM CRF-
stimulated ACTH release were compared to that of 40mM KC1 (Figure 4.7). Figure
4.7a shows the ACTH release induced by O.lnM CRF alone and in combination with
lOpM clofilium, lOpM astemizole or 40mM KC1 before and after lOOnM
corticosterone pretreatment. Inhibitory effect of lOOnM corticosterone on O.lnM
CRF-stimulated ACTH release was significantly attenuated in the presence of lOpM
clofilium or lOpM astemizole, similar to the antagonism of corticosterone inhibition
seen in the presence of 40mM KC1 (Figure 4.7b).
Since clofilium and astemizole appear to reduce corticosterone inhibition, the effects
of these compounds were analyzed in further detail. The dose response analysis of
clofilium (Figure 4.8a) and astemizole (Figure 4.8b) indicated that at lOpM, the
inhibitors significantly increased the ACTH response to O.lnM CRF in the presence
of lOOnM corticosterone pretreatment. This concentration (lOpM) was also the
maximal non-toxic concentration that could be used for ACTH secretion studies in
rat anterior pituitary cultures. Cells started to detach from the culture dishes when
these inhibitors were used at concentrations higher than lOpM. Clofilium (lOpM)
had no significant synergistic effect on the ACTH response to O.lnM CRF (Figure
4.9a) but shifts the curve for the concentration dependent inhibition of O.lnM CRF-
stimulated ACTH release by corticosterone (lOnM-lOOnM) to the right by an order
ofmagnitude (Figure 4.9b). Astemizole (lOpM) had no significant effect on O.lnM
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CRF-induced ACTH release (Figure 4.10a) and markedly reduced the efficiency of
corticosterone (30nM-1000nM) inhibition of O.lnM CRF-induced ACTH release
(Figure 4.10b).
In sum, the data suggested that clofilium- and astemizole-sensitive ion channels, in
particular, KvLQTl/IsK-type and/or HERG-type K+-channels may be involved in
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Figure 4.7: Effect of lOpM clofilium (CLOF), lOpM astemizole (AST) and 40mM
KCl on ACTH release elicited by 0. InM CRF after pretreatment with vehicle or
lOOnM corticosterone (CORT). Columns are means, bars indicate SEM, n=4-
6/group. (a) The empty columns show ACTH release by vehicle treated cells and the
hatched columns show release after treatment with lOOnM corticosterone. Basal
ACTH release is 110.3± 10.6 fmol/well. *P<0.05 when compared to corresponding
vehicle treated release, 1-way ANOVA followed by contrast of means, (b) Data are
expressed as % change in the amount of ACTH release caused by corticosterone
when compared with the respective control groups shown in (a). **P<0.05 when
compared with CRF alone, 1-way ANOVA followed by Dunnett's test. Results
shown are representative of 2 experiments.
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4.1.5b Effect of cadmium on CRF-induced ACTH release and cAMP accumulation in the
presence ofclofilium or astemizole
To investigate whether ACTH secretory mechanisms (in particular, requirement of
[Ca2+]i increase for secretion) normally utilized by CRF were modified in the
presence of clofilium and astemizole, the effect of a commonly used inorganic
9+ 9+
divalent ion Ca -channel blocker Cd was tested.
CRF (O.lnM)-elicited ACTH release was completely abolished by O.lmM CdSC>4
(Cd2+)(Table 4.5). The ACTH response induced by the combination of O.lnM CRF
and lOpM clofilium or 10pM astemizole was significantly reduced but not abolished
by O.lmM Cd2+ added 30 min before and during the stimulation with the
secretagogues (Table 4.5). Cd2+ (O.lmM) inhibited the ACTH response to O.lnM
CRF/lOpM clofilium and O.lnM CRF/lOpM astemizole by 58.7±6.4% (n=4) and
62.5±4.7% (n=2) respectively. Since lOOnM corticosterone blocked 40% and 25%
of the ACTH response to O.lnM CRF in the presence of 10pM clofilium and lOpM
astemizole respectively (see Figure 4.7b), it appears that corticosterone blocked all of
9_l_
the Cd -sensitive ACTH response to 0. InM CRF in the presence of these drugs.
9 i
Cd (O.lmM) pretreatment had no effect on basal cAMP accumulation but
significantly enhanced the cAMP response elicited by O.lnM CRF (Figure 4.11).
These results indicate that ACTH secretion elicited by a combination of CRF with
9-1
clofilium or astemizole is largely dependent on [Ca ]i, therefore largely similar to
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the mechanism of CRF-induced release. Furthermore, the suppression of ACTH
secretion by Cd is not caused by a suppression of cAMP levels. Nonetheless,
distinct mechanism(s) could be mediating ACTH secretion elicited by CRF in the
presence of clofilium or astemizole given that Cd2+ completely blocked CRF-induced




Blocking Ca2+ entry with cadmium reduced secretagogue-evoked
ACTH response in normal rat corticotrophs
Veh Cd
Veh 108.36 ±3.28 (4) 117.72 ± 10.67 (3)
CRF 241.99 ± 10.95 (4) 132.55 ±5.69 (4)
CRF±CLOF 243.70 ± 18.42 (4) 164.22 ±8.71 (4)*
CRF±AST 270.57 ± 13.59 (2) 169.24 ±7.70 (2)*
CRF±KC1 338.58 ± 10.83 (3) 142.51 ± 15.86 (3)
Table 4.5: Effect ofO.lmM CdS04 (Cd2+) on O.lnM CRF-stimulated ACTH release
alone or in combination with lOpM clofilium (CLOF), lOpM astemizole (AST) or
40mM KC1. Data show ACTH release expressed in fmol/well and represent
means±SEM. Cells were pretreated for 30 min with Cd2+, CLOF and AST
accordingly before being challenged with the various secretagogues. *P<0.05 when
compared to cells treated only with Cd2+ alone, 1-way-ANOVA followed by
Student-Newman-Keuls' test. Values shown in parentheses indicate the number of




cAMP accumulation elicited by CRF is enhanced by Cd2+ in primary
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Figure 4.11: Basal cAMP accumulation (filled circles)-, O.lnM CRF (filled
triangles), 0.1mM CdS04 (Cd2+, empty circles) and CRF+ Cd2+ (empty triangles)
induced cAMP accumulation over 60 min. Data represent means±SEM, n=3/group.
Basal cAMP accumulation at 0 min is 117.46±5.90 fmol/well. *P<0.05 when
compared to cAMP response elicited by CRF+ Cd2+ at 10 min. Results shown are
representative of 2 experiments.
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4.1.5c More specific KvLOTl/IsK and HERG-tvve K*-channel inhibitors failed to modify
corticosterone inhibition
As clofilium and astemizole are not highly specific inhibitors of KvLQTl/IsK-type
(Folander et al., 1990; Yamagishi et al., 1995) and HERG-type K+-channel inhibitors
(Berul & Morad, 1995), the effects of more specific inhibitors of these K+-channels
were investigated.
Increasing concentrations of chromanol 293B (a specific KvLQTl/IsK-type K+-
channel inhibitor, (Bleich et al., 1997; Busch et al., 1996; Suessbrich et al., 1996))
and WAY-123,398 [a potent inhibitor of the cardiac delayed rectifier K+-current,
(Ellingboe et al., 1992; Spinelli et al., 1993)], did not significantly modulate the
ACTH response elicited by 0.1 nM CRF in the absence and presence of lOOnM
corticosterone pretreatment (Figure 4.12). Qualitatively similar results were obtained
with the specific HERG-type K+-channel inhibitors, dofetilide (Carmeliet, 1992;
Duff et al., 1995; Fiset et al., 1996) and E4031 (Feng et al., 1997; Heath & Terrar,
1996; Sanguinetti & Jurkiewicz, 1990) (Figure 4.13). The effects of these 4
inhibitors on corticosterone (lOOnM) inhibition of O.lnM CRF-stimulated ACTH
release are summarized in Table 4.6 (chromanol 293B and WAY-123398) and Table
4.7 (dofetilide and E4031). In contrast to lOpM clofilium, 50pM chromanol 293B
and lOpM WAY-123,398 had no significant effect on lOOnM corticosterone
inhibition of the O.lnM CRF-elicited ACTH response (Table 4.6). The HERG-type
K+-channel blockers dofetilide (10pM) and E4031 (lOpM) similarly had no
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discernible effect on lOOnM corticosterone inhibition, in contrast to 10pM
astemizole (Table 4.7).
The data shown here appears to exclude the specific involvement of KvLQTl/IsK-
type and HERG-type K+-channels in corticosteroid inhibition of stimulated ACTH
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Figure 4.12: Effect of (a) WAY-123,398 or (b) chromanol 293B on O.lnM CRF-
evoked ACTH response in the absence and presence of lOOnM corticosterone
(CORT) pretreatment. Data represent means±SEM, n=4-6/group. Basal ACTH
release is 72.41±11.06 fmol/well. ACTH release elicited by lOpM WAY 123,398 or
50pM chromanol 293B alone are 66.51±11.59 fmol/well and 82.05±23.10 fmol/well
respectively. Where error bars are not visible, the SEM bar is less than the space
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Figure 4.13: Effect of (a) E4031 or (b) dofetilide on ACTH response to O.lnM CRF
in the absence and presence of lOOnM corticosterone (CORT) pretreatment. Data
represent means±SEM, n=4/group. Basal ACTH release is 51.28±4.87 fmol/well.
ACTH release elicited by lOpM E4031 or lOpM dofetilide alone are 55.69±8.43




Specificcardiadel yedr t fier(KvLQTl/IsK-type)-channelinhibitorsinal rcorti ost ro inhibitionofCRF-stimulatedACTHreleasenormalacorticotr phs
CRF CRF+CORT
Veh 206.86±15.37 (100±11.43%) 93.77±15 36 (15.89±11.42%)
293B 178.66±6.12 (100±15.17%) 109.30±6 08 (34.72±5 3%)
WAY 184.97±13.35 (100±11.86%) 96.80±11 47 (21.67±10.19%)
CLOF 256.79±4 13 (100±2.24%) 236.29±12.57 (88.88±6. 2%)*
Table4.6:Effectof50pMchromanol293B(293 ),lOWAY-123398WAY)ndlofiliumCLOFlOO corticosterone(CORT)inhib tionfO.lnMCRF-stimulatedA THreleas .Dah wr lexpresfmol/wella d representm ans±SEM(n=5-6/g oup).Basalrele ewa72.41±11.06fmol/w l .V u si parenthes srepr ntp rc agesf controlACTHrelease(means±SEM,n=4/group)sdefi edi s ction2.7.2.Stat sticalanalysisofthff ctCORTwc rr outnthedataexpressedpercent ges(v lu sinar th ses)fr sp ctivestimulus-evokr ea .*p<0.05wh nco pared
toCRF±CORTalone,1-way-AN VAfoll wedbyStudent-Newm n-Keuls'st.R ultssh wnrrepresentativef2exp rim n .
Table4.7
InhibitionofHERG-typeK+channelsdidnotal erortic stero eiCRF-st mulat dACTHrelease innormalratcorticotrophs VehE4031Dof tilideAST CRF183.39±5.42200 956.481 206.93615.71 (100±4.08%)31 .438 45 CRF±CORT89.37±6.44110.294 6208 92 78 817. 0 (29.30±4.84%)3 789.71%)5 967 8273 96* Table4.7:EffectoflOpM4031,10do etilideans emizole(AST)nl O Mcor icoster neC RTinhib tion 0.1nMCRF-stimulatedACTE1releas .DathowTHseexpresifmol/wellndentm ns±SE(n=4/group). Basalrelasew s50.39±3.81fmol/wel .V luinparenthe spresentcentagfco trolACTHl( eans±SEM, n=4/group),asdefinedi section2.7.2.Stat sticalnalysisofheff ctCORTwcarr edutnaexpre se percentages(valuesinar nth ses)ofthr spectivestim lus-evokedl as .*p<0.05wh ncomp rCRF±CORTon ,1- way-ANOVAfollowedbyStudent-Newman-Keuls' st.
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4.1.6 Discussion
4.1.6a Are the novel fC-channels underlying the cardiac delayed rectifier currents of any
functional importance in early glucocorticoid feedback inhibition in normal rat
corticotrophs?
Consistent data from pharmacological studies in cultured rat anterior pituitary cells
with clofilium and astemizole pointed to the potential involvement of the K+-
channels underlying the cardiac delayed rectifier currents (see section 4.1.5a) in
glucocorticoid inhibition in normal rat corticotrophs. Subsequent analysis with
WAY-123,398, chromanol 293B, E4031 and dofetilide did not consistently
reproduce the effects seen with clofilium and astemizole in these rat anterior pituitary
primary cultures.
4.1.6b KvLQTl/IsK-tvve tC-channels
Chromanol 293B had no effect on the ACTH secretory response to CRF with or
without corticosterone pretreatment (Table 4.6). Since this chromanol derivative has
been reported to be specific for blocking KVLQTl/IsK-type K+-channels (Busch et
al., 1996; Suessbrich et al., 1996), it appears that these K+-channels are unlikely to
have any functional importance in early glucocorticoid inhibition of the ACTH
response elicited by CRF in normal rat corticotrophs. Chromanol 293B is
purportedly an open channel blocker (Busch et al., 1997) and the KvLQTl/IsK K+
currents have a very slow rate of activation (Boyle et al., 1987). However, the
apparent lack of effect of chromanol 293B is unlikely to be due to an absence of
activated (open) KvLQTl/IsK K+-channels since the blocker was pretreated for 30
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min before fresh drug was added again with secretagogue for a further lh (see
section 2.3 and Figure 2.1). There is also indication that the drug may penetrate the
cell to block the K+-channel (Loussouam et al., 1997).
With respect to clofilium, initial data (section 4.1.5a) suggested the involvement of
KvLQTl/IsK-type K+-channels in the inhibitory action of glucocorticoid. However,
these compounds may modulate other K+-channels (Berul & Morad, 1995; Folander
et al., 1990; Yamagishi et al., 1995) and may even have effects unrelated to K+-
channel blockade (Rabinowitz et al., 1997; Silver et al., 1989). For instance,
9+
clofilium has been reported to modulate Ca /calmodulin-activated PDE activity
through antagonism of calmodulin (Silver et al., 1989). This may explain the
observation in preliminary experiments that clofilium had a tendency to decrease
CRF-induced cAMP response (Lim, not shown). In addition, a recent study
(Rabinowitz et al., 1997) reported the observation that clofilium triggers a sustained
increase in acid release at concentrations similar to those used in this study in some
human and murine cell lines. Thus, clofilium may produce undesirable effects on
cellular metabolism and may account for the cytotoxic effect seen in the cultured rat
anterior pituitary cells when treated with higher concentrations (more than 10pM) of
clofilium (section 4.1.5a). Furthermore, since Cd2+ could not completely block
ACTH secretion elicited by the combination of CRF and clofilium (while CRF-
induced secretion was completely inhibited, see section 4.1.5b), it is possible that
clofilium may perhaps have some non-specific toxicity that caused ACTH leakage
from the cultured rat corticotrophs. Nonetheless, it appears that CRF stimulated
ACTH release in the presence of clofilium (lOpM) treatment (section 4.1.5b) is
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largely dependent on Ca2+, suggesting that the ACTH secretory pathway activated by
CRF is fundamentally intact. Since clofilium has been known to block other types of
K+-channels besides KvLQTl/IsK-type channels (Folander et al., 1990; Yamagishi
et al., 1995), it is likely that the antagonism of glucocorticoid inhibition by clofilium
seen in cultured rat anterior pituitary cells may involve modulation of other class(es)
of K+-channels. Moreover, the IsK protein has not been so far found to be expressed
in rat brain (Sugimoto et al., 1990). There appears to be only one report to date
documenting the possible presence of the IsK protein in rat neurohypophysial nerve
terminals based on the observation of KvLQTl/IsK-like K+ currents (Kilic et al.,
1996).
Taken together, these observations suggests that functional KvLQTl/IsK-like K+-
channels are not fundamentally important for glucocorticoid inhibition in normal rat
corticotrophs.
4.1.6c HERG-type K*-channels
The methanesulphonanilides E4031 and dofetilide are specific inhibitors of HERG-
type K+-channels (see section 4.1.5c). Both drugs have been found to bind to some
form of endogenous receptor (methanesulphonanilide receptor) that is closely
associated with HERG-channels (Duff et al., 1995; Sanguinetti et al., 1995).
Furthermore, Sanguinetti and colleagues have found that concentrations of E4031
similar to that used in this study failed to block a HERG current expressed in
Xenopus oocyte (Sanguinetti et al., 1995). Therefore, it is possible that the apparent
lack ofmodulation of glucocorticoid inhibition in normal rat corticotrophs by E4031
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and dofetilide may be due to the absence of an additional subunit required for drug
sensitivity.
The second generation HI antagonist astemizole has been extensively shown to
block HERG-type K+-currents (Suessbrich et al., 1996; Taglialatela et al., 1998;
Woosley, 1996), although it has been reported to block A-type transient outward K+
currents as well (Berul & Morad, 1995). The effects of astemizole on glucocorticoid
inhibition of CRF-elicited ACTH response seen in cultured rat anterior pituitary cells
(section 4.1.5a) is intriguing given the lack of such an effect by E4031 and dofetilide
(section 4.1.5c). It may be possible that some as yet unknown effect related to the
antihistaminergic actions of astemizole, is somehow causing the reduction of
glucocorticoid inhibition seen in normal rat corticotrophs.
4.1.6d Conclusion involvement ofnovel K*-channels in early glucocorticoid feedback
inhibition
Data presented in this section has shown that clofilium and astemizole consistently
and reproducibly attenuated early glucocorticoid inhibition of CRF-stimulated
ACTH secretion in primary cultures of rat anterior pituitary cells. If the effects of
clofilium and astemizole are indeed through inhibition ofK+-channels, then these K+-
channels are likely to be of novel and as yet unidentified type(s). Furthermore, it is
possible that clofilium and astemizole block multiple K+-channels, including TEA-
sensitive and TEA-insensitive K+-channels. The blockage ofboth TEA-sensitive and
TEA-insensitive K+-channels may be required to achieve sufficient depolarization
that is needed to oppose the effects of glucocorticoid induced proteins in primary
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cultures of rat anterior pituitary cells. Hence, when only specific K+-channel
blockers were used (see section 4.1.5c), there was no significant effect on
glucocorticoid action. In contrast, blockade of TEA-sensitive K+-channels was
adequate to counteract the inhibitory action of glucocorticoids on CRF-evoked
ACTH secretion in AtT20 cells (see section 4.1.2b).
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4.2 Analysis of the effect of sustaining cAMP accumulation on
early glucocorticoid inhibition in primary cultures of rat
anterior pituitary corticotrophs
4.2.1 Introduction
Previous studies have demonstrated the importance of the regulation of intracellular
cAMP metabolism through Ca2+-dependent feedback in early glucocorticoid
inhibition in AtT20 cells (see Section 1.2.4). As this Ca2+-dependent feedback
mechanism may also evident in normal rat corticotrophs (Antoni, 1995), the
objective of this section of the thesis is to examine the role this Ca -mediated
feedback mechanism in glucocorticoid inhibition in cultured rat adenophypophysial
corticotrophs.
The physiological hypothalamic regulator of ACTH secretion, AVP, has been
previously proposed to reduce glucocorticoid feedback in vitro (Bilezikjian et al.,
1987) and in vivo (Antoni, 1993; Deuster et al., 1998; Scaccianoce et al., 1991; Scott
& Dinan, 1998; von Bardeleben et al., 1985). However, the underlying cellular
mechanism for the resistance of AVP to glucocorticoid action at the pituitary
corticotroph are not well understood. Recent studies cf (Antoni, 2000) have
suggested that in the presence of AVP, the elevation in CRF-mediated cAMP
response may be a consequence of bypassing the Ca2+-dependent feedback. Hence,
the effects of AVP on CRF-induced cAMP and ACTH responses as well as on
glucocorticoid feedback inhibition were analyzed.
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Other notable components of the Ca2+-mediated feedback mechanism include PDEs
and calcineurin (Ca2+/calmodulin activated protein phosphatase, PP2B). Inhibition
of these components could potentially modulate glucocorticoid inhibition of
stimulated ACTH release (see section 1.2.4). Therefore, the effects of rolipram (a
relatively selective inhibitor of cAMP-dependent PDE) and immunosuppressant




4.2.2 Sustaining CRF-induced cAMP at elevated levels with AVP
4.2.2a cAMP response to CRF andA VP
There was no effect of 2nM AVP on intracellular cAMP levels at any time point
tested (Figure 4.14a). The cAMP levels increased 2.5-fold over basal in response to
0.1 nM CRF and remained unchanged over 60 min. AVP enhanced CRF-induced
cAMP accumulation at all time points examined, and although cAMP levels
measured at 60 min were lower when compared with levels at 10 min, they were still
3 times higher than with CRF alone (p<0.05, n=4/group, 1-way-ANOVA, Dunnett's
test) (Figure 4.14a).
In summary, the data show the significant enhancement of CRF-induced cAMP
accumulation in the presence ofAVP over 60min.
4.2.2b CRF-evoked ACTH response was resistant to corticosterone inhibition in the
presence ofA VP
AVP (2nM) alone had no significant effect on basal ACTH release but markedly
potentiated the ACTH response to O.lnM CRF (Figure 4.15a). Corticosterone (10-
lOOnM) dose-dependently inhibited O.lnM CRF-evoked ACTH release (Figure
4.15b). The degree of corticosterone (10-lOOnM) inhibition of ACTH release




Hence, the synergistic cAMP response elicited by CRF and AVP correlates with the




4.2.3 Sustaining CRF-induced cAMP at elevated levels with rolipram
4.2.3a cAMP response to CRF and rolipram
The type 4 PDE inhibitor rolipram (O.lmM) elicited a small but significant increase
(1.7-fold) in cAMP accumulation over basal cAMP levels. Basal cAMP
accumulation remained unchanged while the cAMP response to O.lmM rolipram
significantly increased over 60 min (Figure 4.14b). CRF (O.lnM)-induced cAMP
accumulation remained unchanged and was consistently potentiated by O.lmM
rolipram over 60 min. The cAMP response elicited by a combination ofO.lnM CRF
and O.lmM rolipram significantly increased over 60 min (Figure 4.14b).
4.2.3b Corticosterone inhibition ofCRF-inducedACTH release was reduced by rolipram
CRF (O.lnM) elicited a 2.5-fold increase over basal ACTH release while O.lmM
rolipram had no significant effect on basal ACTH release (Figure 4.16a). Similar to
the effect of 2nM AVP, O.lmM rolipram produced a synergistic increase of O.lnM
CRF-evoked ACTH release (Figure 4.16a). The combination of O.lnM CRF and
O.lmM rolipram elicited an ACTH response that was much less effectively inhibited
by corticosterone (10-lOOnM) (Figure 4.16b).
These results show that rolipram potentiated the cAMP response elicited by CRF.
This correlates with the potentiation in ACTH release and is associated with a
marked resistance to corticosterone inhibition.
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Figure4.14:MeasurementofcAMPaccumulatioinult redranteriorpi arycells.Columnsrm ans,baind tSE , n=4/group.*P<0.05whencomparedtbas lcAMPlevelsmeasuredtcorrespon ingtip ints,1- yANOVAfollo dyNewma - Keulst st,(a)BasalcAMPlevemea uredt0tipointis153.11±7.44fmol/w ll.#P<0.05rthin r ct onbetw eO.lnMCRFand 2nMAVP,-wayNOVA.(b)BasalcAlevemeasuredt0ti epointis205.72±10.18fmol/w ll.P<0.05rthin er ction between0.1nMCRFandmrolipram(R li).**P<0.05wh ncompar dt rrespondingAMPa cu ul ti nmeas relO i . Resultsshownarerepresentativeof2x erimen s.
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Figure4.16:(a)ACTHresponseto0.1nMCRFndmroli ramR li).S lic l mnsree s,ba sindicatE ,n=4/g oup. tP<0.05fortheinteractionbetwe nCRFandrolip am,2- yANOVA.(b)oncentratiod p de ti hibitiofO.l MRF-evoked ACTHreleasebycorticosteroneinthabs ncndpresef0.1mMr lipr m.D trexpre sedc nttrolre e (definedinsection2.3.1)a drepresentm a ±SEM,=4/group.*P<0.05whcomparedt rr po dingCRFg ou ,1-w yANOVA followedbycontrastfmeans.Resultshownarrepr sent tive4exp im nts.
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4.2.4 Discussion
The data presented in this section demonstrate that exaggerated cAMP responses lead
to resistance to glucocorticoid inhibition of CRF-stimulated ACTH secretion. This
effect of blunting the glucocorticoid response could be achieved by using either AVP
or rolipram.
Previous studies have presented a disparate picture of the effect of glucocorticoids on
secretagogue-induced cAMP accumulation in the anterior pituitary corticotropin
Several studies have found that glucocorticoids may decrease CRF-stimulated cAMP
production by up to 50% (Bilezikjian & Vale, 1983; Sobel, 1985; Vale et al., 1983).
However, cells were exposed to glucocorticoids for much longer than 2 h (the
duration of glucocorticoid exposure in our studies) in these studies. In contrast, other
studies have shown that glucocorticoids have no effect on CRF-evoked cAMP
accumulation (Abou-Samra et al., 1986; Dartois & Bouton, 1986; Giguere et al.,
1982), suggesting that the steroid acts at a step subsequent to cAMP production and
accumulation.
The synergistic ACTH response to CRF and AVP is well established in vitro and in
vivo (Brooks & Challis, 1989; DeBold et al., 1984; Keller-Wood, 1998; Milsom et
al., 1985). In anterior pituitary corticotrophs (Koch & Lutz-Bucher, 1989; Murakami
et al., 1984; Vale et al., 1983), the potentiation ofCRF-induced cAMP and ACTH by
AVP appears to be a robust and physiologically relevant phenomenon (Rivier &
116
Results
Vale, 1983). This is despite the fact that different concentrations of CRF and AVP,
as well as different durations of stimulation by these secretagogues used in various
studies (Abou-Samra et al., 1987; Bilezikjian et al., 1987; Carvallo & Aguilera,
1989; Hoffman et al., 1985; Yates et al., 1971). In our experiments, we used
physiological concentrations of AVP (2nM) and CRF (0.1nM) to demonstrate the
synergistic stimulation of cAMP accumulation and ACTH secretion elicited by CRF
in primary cultures of anterior pituitary corticotrophs (see section 4.2.2a). When
cells were stimulated with CRF and AVP concomitantly, the inhibitory effect of
corticosterone on stimulated ACTH secretion was markedly attenuated (section
4.2.2b). The role of AVP in modulating glucocorticoid feedback and subsequent
alteration of the HPA axis activity may have important implications for
understanding the pathophysiology of diseases like depression (Scott & Dinan,
1998). Thus, it would be important to understand the mechanism by which AVP
potentiates CRF-induced ACTH secretion, and which is highly resistant to
glucocorticoid inhibition. It has been shown that protein kinase C (PKC) plays a
principal role in mediating the potentiating effects ofAVP on CRF-stimulated ACTH
secretion and cAMP accumulation at physiological levels in corticotrophs (Abou-
Samra et al., 1986; Abou-Samra et al., 1987; Carvallo & Aguilera, 1989; King &
Baertschi, 1990). Work in anterior pituitary homogenates has shown that AVP
reduces PDE activity by 30%, plausibly through PKC and may partly explain the
experimental observation that AVP potentiates CRF-induced cAMP accumulation
(Abou-Samra et al., 1987).
117
Kesuits
Whether early glucocorticoid inhibition of stimulated ACTH secretion targets cAMP
accumulation/production in the corticotroph remains debatable. Data presented here
show that ACTH secretion elicited by non-hydrolyzable cAMP analogues like CPT-
cAMP is inhibited by glucocorticoids (section 4.1.2a and 4.1.2c), consistent with
data from other studies (Bilezikjian & Vale, 1983; Giguere et al., 1982). Therefore,
it appears that glucocorticoid inhibition may not involve modulation of cAMP levels
per se. Instead, the intracellular mediators of glucocorticoid inhibition could include
enzymes involved in the metabolism of cAMP.
Our data with rolipram (section 4.2.3) suggest that the type IV cAMP-dependent
PDE is present in normal rat corticotrophs. By blunting the downregulation of
cAMP signals (through inhibition with rolipram) by PDE IV, intracellular cAMP was
elevated to levels that could reduce early glucocorticoid inhibition.
Therefore, using different physiological means (AVP and rolipram) to induce higher
than usual levels of cAMP in cultured rat anterior pituitary cells, early glucocorticoid
inhibition was significantly attenuated. cAMP is the primary mediator of CRF-
induced ACTH secretory pathway in corticotrophs. Its main effector, PKA
modulates distinct components in the pathway to increase [Ca2+]i which ultimately
leads to ACTH secretion (see section 1.2.4). It appears that driving cAMP to
exaggerated levels (by the physiological methods mentioned above) can potentially
overcome the inhibitory effect of glucocorticoids on components of the secretory
pathway. For instance, cAMP acting through PKA may inhibit K+-channels and
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cause cell depolarization. This is in opposition to the effect of glucocorticoids,
which appears to be maintenance of the membrane potential.
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4.3 Analysis of the role of protein phosphorylation in early
glucocorticoid inhibition of ACTH release
4.3.1 Introduction
Previous pharmacological evidence have strongly indicated that calcineurin, a
9+
Ca /calmodulin activated serine/threonine phosphatase (protein phosphatase 2B)
may be involved in glucocorticoid early inhibition in AtT20 cells [see section 1.3.3
and (Shipston et al., 1994)]. Hence, immunosuppressants such as FK506 and
cyclosporin A (CsA), potent inhibitors of calcineurin (Liu et al., 1991; Schreiber,
1992), were tested to examine whether these drugs also modulate glucocorticoid
inhibition, in cultured rat anterior pituitary cells. FK506 and CsA act by binding to
soluble intracellular receptor proteins, which are the FK506 binding protein-12
(FKBP-12) and cyclophilin respectively and inhibits their cis-trans peptidyl-prolyl
isomerase (PPIase) activity . These ligand-immunophilin complexes binds and
inhibits the phosphatase activity of calcineurin (Kunz & Hall, 1993; Liu et al., 1991;
Schreiber, 1992) (independently of their effect on PPIase, (Schreiber, 1991; Sigal &
Dumont, 1992), by possibly excluding phosphopeptide binding in the enzyme's
active site (Clipstone et al., 1994; Salowe & Hermes, 1998). The compound, L-
685,818, which binds and inhibits the PPIase activity of FKBP-12 but has no effect
on calcineurin, was tested as a control to show that the effects of FK506 are elicited




4.3.2 Effects of immunosuppressants on stimulated ACTH secretion
4.3.2a ACTH response to increasing concentrations ofFK506
Analysis of increasing concentrations of FK506 showed that 2pM FK506 alone
elicited a small (1.6-fold) but statistically significant increase over basal ACTH
release and caused a significant enhancement of the ACTH response to 0.3nM CRF
(Figure 4.17a). No effect of 0.08pM and 0.4pM FK506 on 0.3nM CRF-stimulated
ACTH release was observed (Figure 4.17a).
4.3.2b Potency of corticosterone inhibition was markedly reduced by immunosuppressant
drugs
CRF (O.lnM) elicited an ACTH response that was dose-dependently inhibited by
corticosterone (10-lOOnM) (Figure 4.17b). Pretreatment with 2pM FK506 reduced
the apparent potency of corticosterone (10-lOOnM) to inhibit O.lnM CRF-evoked
ACTH response by more that 10-fold (Figure 4.17b).
FK506 (2pM) and cyclosporin A (2pM) had no significant effect on basal ACTH
release. Both drugs potentiated the ACTH response to O.lnM CRF and was
significantly less inhibited by lOOnM corticosterone (Table 4.8). The compound L-
685,818 had no significant effect on basal and O.lnM CRF-induced ACTH release
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and also did not modify the corticosterone (lOOnM) inhibition of 0.1nM CRF-evoked
ACTH response (Table 4.8).
To summarize, the data show that inhibition of calcineurin markedly attenuates early
glucocorticoid inhibition of stimulated ACTH release in normal rat corticotrophs,
extending the observations made in AtT20 cells.
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Figure4.17:(a)Concentrationdep d ntstimulationofACTHrele sebyFK506vehiclndCRFtr a dc ll .lum sarea s, barsindicateSEM,n=4/group.fP<0.05whencomparedtc re pondingont lg up(wit utFK5 6),1-wayANOVAfoll y Dunnett'stes ,(b)Concentra iondep dentinhibitioof0.1MCRF-evokedACTHr lea ebycor c steroneithabs cnpresen of2pMFK506.Datareexpressedpe c ntfcontrolACTHr l se(d fiinse i n2.3.1)rmean ±SEM,n=4/g up. *P<0.05whencomparedtc rrespondingCRFg oup,1-wayANOVAfoll webycont stf.FK506addduritla 30minofcorticosteronep etreatme t.Resultsshownarrep en ativef2exp i ts.
Table4.8
InhibitionofCRF-stimulatedACTHrele sebycorticosteroneinnormalatcortic trophsw sreduc d immunosuppressantdr g Vehicle+CRF+CRF/CORT
%inhibition
Vehicle FK506 CsA L-685,818
47.13±2.87 55.61±4.36 56.30±7.82 62.88±8.41
97.53±6.67 163.61±7.64f 172.60±21.55f 97.20±7.73
55.48±3.77 108.01±5 50 113.40±5.06 50.50±1.09
83.43±7.49 47.74±.72* 47.19±12 01* 93.27±2.18
Table4.8:EffectlOOnMcorticost rone(CORT)n.lCRF-stimula edACTHr le sithpre ncef2FK506, cyclosporinA(C A)and20pML-685,818iratnter orpi u aryellsult edserum-freem dium(defineecti n.2 supplementedwith4nMCORT.FK506,sAandL-68 ,818werdded ringthlast3mofCORTr tr atment.Datahow ACTHreleaseexpres edinfmolp rw llor%inhibition,hichrepre ntst perc ntagei i itionfcontr lACTHr l asby CORTasdefinedisection2.7.2.V lu sr pr se tmeans±SEM(n=4/g oup).St tis cala aly isofhffecCORTwac rri d outnthedataexpressed%inhibition.*p<0.05whecomparedin ibitionfCRF-sti ulatACTHrele se,1-way- ANOVAfollowedbyDunnett'stes ,p<0.05f rhint ractionbet eCRFne p ctivedrug ,2-way-ANOVA.Re ults shownarerepresentativeof2xperime ts.
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4.3.3 Discussion
The results presented in this section provide strong pharmacological evidence that
calcineurin is an important component of early glucocorticoid inhibition of
stimulated ACTH secretion in cultured rat anterior pituitary cells. This is consonant
with previous pharmacological evidence obtained in AtT20 cells (Shipston et al.,
1994).
4.3.3a Potential functions ofcalcineurin in pituitary cells
One of the first physiologically relevant functions implicated for calcineurin in
pituitary corticotrophs was an inhibitory role in ACTH secretion in AtT20 cells.
Consistent with previous findings in AtT20 cells (Antoni et al., 1993), FK506
significantly enhanced the ACTH secretory response to CRF in normal rat
corticotrophs, suggesting a similar inhibitory role for calcineurin in stimulus-
secretion coupling. Greater understanding of the role of calcineurin in other anterior
pituitary cell types is emerging. A recent study in cultured rat anterior pituitary cells
found that the stimulation of growth hormone release from somatotroph cells by
FK506 was mediated through inhibition of calcineurin which resulted in the
activation of cAMP-dependent protein kinase signally pathways (Ohye et al., 1998).
In rat gonadotrophs, calcineurin has been localized to the cytosolic and nuclear
fractions and is postulated to mediate the actions of gonadotrophin release hormone
(Natarajan et al., 1991). Calcineurin has also been implicated in the regulation of
cell proliferation in cultured pituitary cells (Florio et al., 1996). The regulation of
Ca2+-channel activity and exocytosis in rat lactotrophs is reciprocally controlled by
protein kinase C and calcineurin (Fomina & Levitan, 1997).
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4.3.3b Potential targets for calcineurin regulation and their relevance to early
glucocorticoid inhibition in normal rat corticotrophs
Adenyl Cyclase 9
Previous work has shown that CRF-stimulated eAMP accumulation in AtT20 cells is
inhibited by intracellular Ca2+ and that this effect was suppressed by FK506 (Antoni
et al., 1995). This suggested that calcineurin formed a Ca2+ sensor negative feedback
loop on CRF-stimulated cAMP accumulation. Importantly, the inhibition of
calcineurin by FK506 (which would result in a disruption of the Ca2+-dependent
negative control of cAMP levels) was associated with a marked reduction in the
potency of dexamethasone to inhibit CRF-elicited ACTH release (Shipston et al.,
1994). Therefore, it appears that the mechanism of glucocorticoid inhibition may
involve modulation of this Ca2+ feedback control of cAMP through calcineurin in
AtT20 cells. Further studies established an association of the effect of calcineurin on
cAMP synthesis with the expression of a novel adenylyl cyclase isotype (AC9)
(Antoni et al., 1995), identified as the major isotype in AtT20 cells and a potential
target of calcineurin-mediated inhibition of cAMP synthesis (Antoni et al., 1998;
Paterson et al., 1995). Although the notion that AC9 is modulated by calcineurin is
controversial since other workers (Premont et al., 1996) have reported no effect of
2_|_ .Ca /calmodulin on AC9 over-expressed in Sf9 insect cells, observations on the




The Ca2+ feedback control of intracellular cAMP is likely to be operative in normal
rat corticotrophs as well. Firstly, mRNA for AC9 is also present at relatively high
levels in rat adenohypophysis (Smith, SM, Paterson, JM, Simpson, J & Antoni, FA,
unpublished). Secondly, in acutely dispersed rat adenohypophysial cells, depletion
94-
of rapidly mobilisable Ca stores produced a marked enhancement of the cAMP
response to CRF (Antoni, 1997; Antoni, 1995). My own studies described in section
4.1.5b showed that Cd2+ significantly increased the cAMP accumulation elicited by
94- 9+
CRF in cultured rat anterior pituitary cells. As Cd blocks Ca through most
known Ca2+-channels, these findings are in agreement with the notion that Ca2+
inhibits CRF-induced cAMP accumulation.
Taking together the data presented in this section and other work done in this
laboratory (Antoni et al., 1995; Antoni et al., 1998; Paterson et al., 1995; Shipston et
al., 1994), it is reasonable to hypothesize that calcineurin may also target adenylyl
9+
cyclase and mediate the Ca -dependent control of cAMP metabolism in normal rat
corticotrophs. Importantly, glucocorticoid may act through calcineurin (potentially
9 .
through calmodulin) to sensitize the corticotroph to the Ca"* negative feedback
mode, prematurely terminating Ca2+ signals to levels insufficient for ACTH release.
Other potential sites for calcineurin regulation
Calcineurin has also been implicated in the control of voltage-gated ion channel
activity by modulation of their phosphorylation states (Fomina & Levitan, 1997;
White et al., 1991). In normal rat corticotrophs, it is evident that some class of K+-
channels (though yet to be identified) are vital to early glucocorticoid inhibition.
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These may be substrates for the phosphorylatory control by calcineurin, which is in








The principal purpose of this thesis was to investigate the mechanisms of action by
which early (within 2h) glucocorticoid feedback inhibition of stimulated ACTH
secretion occurs in normal anterior pituitary corticotrophs. This involved verifying a
model for the intracellular mechanism of early glucocorticoid inhibition proposed
based on experiments carried out in the murine corticotroph tumour cell line AtT20
in normal rat corticotrophs.
The following sections will summarize the key experimental findings. Detailed
discussions are found in the relevant sections of Chapter 3 and 4. Further lines of
investigation that can be pursued based on research findings presented in this thesis
will then be proposed under corresponding sections.
5.2 Role of calmodulin in early glucocorticoid feedback inhibition
Experiments to investigate whether calmodulin functions as a primary mediator of
early glucocorticoid feedback inhibition were carried out in AtT20 cells. Two
approaches were used, namely a constitutive calmodulin over-expression system and
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an inducible calmodulin over-expression system were generated in AtT20 cells.
These transfected AtT20 cells were then analyzed for their calmodulin mRNA levels
as well as ACTH secretion characteristics.
Using Northern analysis, several transfected AtT20 clones exhibited elevated levels
of calmodulin mRNA. Functional protein analysis also indicated increased
calmodulin activity in these clones. However, the ACTH response to CRF in these
cells was not significantly different from those of control, wild type AtT20 cells or
cells transfected with the vector alone. It was thus not possible to conclude whether
calmodulin may mediate the early inhibitory actions of glucocorticoids in
corticotrophs. The inducible calmodulin over-expression system set up in AtT20
cells were subsequently found not to be suitable for experimentation since the
doxycycline (the compound used for inducing calmodulin expression) inhibits ACTH
secretion.
Other mammalian inducible expression systems have since become commercially
available. Of note is the ecdysone-inducible expression system from Invitrogen,
which drives gene expression with the analogues of an insect steroid hormone
ecdysone. As Ponasterone A and Muristerone A (the ecdysone analogues) are
reportedly inert to mammalian physiology, the ecdysone-inducible system may be
useful for driving the transient over-expression of calmodulin in AtT20 cells and will
not interfere with the assessment of any modulation of ACTH secretion in these cells.
Therefore, the role of calmodulin as a primary mediator of early glucocorticoid
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inhibition could be better explored using other mammalian inducible expression
systems such as the above-mentioned one.
Role of K+-channels in early glucocorticoid feedback inhibition in
normal rat corticotrophs
Experiments in AtT20 cells have suggested that the BK channels are pivotal for early
glucocorticoid inhibition of CRF-stimulated ACTH secretion. Hence, the role of
BK-channels in glucocorticoid inhibition was investigated in normal rat
corticotrophs.
Pharmacological analysis of K+-channels in primary cultures of rat anterior pituitary
cells showed that blocking BK-channels with charybdotoxin did not significantly
alter the efficiency of early glucocorticoid inhibition of CRF-stimulated ACTH
secretion. Thus, BK-channels do not appear to have an important role in
glucocorticoid inhibition in normal rat corticotrophs, in contrast to AtT20 cells.
Therefore, further pharmacological analysis was carried out using blockers of other
types of K+-channels, namely clofilium and astemizole. In the presence of these K+-
channels inhibitors, glucocorticoid inhibition of CRF-stimulated ACTH release was
significantly blunted in cultured rat anterior pituitary cells. This suggested that there
is probably a population of ion channels (K+-channels) important for maintaining the
membrane potential. In particular, the HERG-type and KvLQTl/IsK-type K+-
channels may be involved. More specific inhibitors for these K+-channels were
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subsequently tested in cultures of rat anterior pituitary cells. These specific
inhibitors did not modulate the inhibitory efficacy of glucocorticoid.
As clofilium and astemizole are relatively unspecific blockers of K+-channels, further
studies are needed to clarify whether K+-channels are indeed important for early
glucocorticoid feedback inhibition using a combination of molecular biological,
biochemical and electrophysiological methods. For instance, a single corticotroph
pre-treated with glucocorticoids can be used for patch-clamp studies to investigate if
K+-currents are modulated by steroid treatment. Additionally, the availability of
pharmacological blockers of K+-channels with greater specificities will also help to
shed light on the identities of the K+-channels important for early glucocorticoid
inhibition in normal rat corticotrophs.
A further aspect is the involvement of K+-channels in early glucocorticoid action
concerns protein phosphorylation. In particular, glucocorticoid-induced proteins may
directly or recruit other signaling pathways to regulate K+-channel activity.
Increasing evidence suggests that K+-channel activity is dynamically regulated by the
interaction of protein kinases and phosphatases closely associated with the channel
complex (Levitan, 1994; Reinhart & Levitan, 1995; White et al., 1993; White et al.,
1991). Recent data in AtT20 cells suggest that glucocorticoids recruit a
dephosphorylation module with a modified PP2A-like phosphatase activity to the
plasma membrane that was closely associated with BK-channels (Tian et al., 1998).
Therefore, probing the role of protein phosphorylation in K+-channel modulation by
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glucocorticoids in normal corticotrophs could be invaluable to the understanding of
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Depolarization counteracts glucocorticoid inhibition of
adenohypophysical corticotroph cells*
'•2-3M.C. Lim, 2M.J. Shipston & 'F.A. Antoni
'MRC Brain Metabolism Unit, Department of Pharmacology, ^Department of Physiology, University of Edinburgh,
Edinburgh EH8 9JZ
1 In AtT20 mouse corticotroph tumour cells large conductance Ca2+-activated K + -channels (BK-
channels) have an essential role in the early glucocorticoid inhibition of adrenocorticotrophin (ACTH)
secretion evoked by corticotrophin-releasing factor. The present study examined whether or not BK-
channels are also pivotal to glucocorticoid inhibition of normal rat anterior pituitary cells.
2 A membrane-permeant, non-metabolizabie cyclic AMP analogue, 8-(4-Chlorophenylthio)adenosine-
3',5'-cyclic-monophosphate (CPT-cAMP) was used as the primary secretagogue stimulus, as this mimics
the increase of intracellular cyclic AMP caused by corticotrophin-releasing factor, but is not subject to
the complex Ca2' -dependent regulation of cyclic AMP metabolism that is evident in corticotroph cells.
3 Experiments in AtT20 cells showed that ACTH secretion stimulated by 1 mM CPT-cAMP was
suppressed to 34+1.5% (n= 12) of the control stimulus by a maximal dose of 100 nM dexamethasone.
The ACTH secretion evoked by the combination of 1 mM CPT-cAMP with either 5 /uM (—)BayK8644
(L-type Ca2+-channel activator) or 5 mM TEA (K '-channel blocker) was respectively 69.1+7.6% and
69.3 + 11.8% of control after 2 h preincubation with 100 nM dexamethasone (P<0.05 vs CPT-cAMP).
The ACTH response elicited by 5 fJM (—)BayK8644 and 5 mM TEA given together was completely
resistant to inhibition by 100 nM dexamethasone. Furthermore, TEA and ( —)BayK8644 given together
synergistically stimulated ACTH release in combination with 0.1 mM or 1 mM CPT-cAMP, and these
ACTH responses were not inhibited by 100 nM dexamethasone.
4 In primary cultures of rat anterior pituitary cells, TEA (up to 20 mM), charybdotoxin (30 nM) or
apamin (100 nM) failed to modify the glucocorticoid inhibition of 0.1 mM CPT-cAMP-induced ACTH
release. The combination of 5 mM TEA and 5 /im (—)BayK8644 elicited a small but significant increase
in ACTH secretion but did not modify the inhibition of 0.3 mM CPT-cAMP-induced ACTH secretion by
100 nM dexamethasone.
5 In primary cultures of rat anterior pituitary cells, depolarization of the membrane potential with
40 mM KC1 enhanced the ACTH response to CPT-cAMP and markedly reduced the maximal inhibitory
effect of dexamethasone to 55+1.2% as well as that of corticosterone to 33 + 2.1% vs 100 + 2.5% and
100+1.9% inhibition respectively, when 0.1 mM CPT-cAMP was used alone. Introduction of 5/(M
( —)BayK8644 with 40 mM KC1 in this system had no additional effect on glucocorticoid inhibition.
6 No glucocorticoid inhibition of ACTH release to any of the stimuli applied was observed in cells
pretreated with the mRNA synthesis inhibitor, 5,6-dichloro-furanosyl-benzimidazole riboside (DRB)
(0.1 mM) or the protein synthesis blocker, puromycin (0.1 mM).
7 In summary, early glucocorticoid inhibition of stimulated ACTH release by cultured rat anterior
pituitary cells was dependent on the synthesis of new mRNA and protein. Depolarization of the
membrane potential potentiated CPT-cAMP-induced ACTH secretion in AtT20 cells as well as cultured
rat corticotrophs and this was associated with a resistance to the early inhibitory effect of
glucocorticoids. Glucocorticoid inhibition in rat anterior pituitary corticotrophs was unaltered by
TEA, charybdotoxin as well as apamin, and hence it is unlikely to involve predominantly BK-or SK-type
Ca2+-activated K +-channels.
8 These results support the thesis that a prime target of glucocorticoid feedback inhibition in anterior
pituitary corticotrophs is the membrane potential and indicate that glucocorticoid-induced proteins
regulate the activities of several distinct plasma membrane ion channels.
Keywords: Pituitary gland; potassium channels; dexamethasone; corticosterone; AtT20 cells; stress
Introduction
Adrenal corticosteroids are powerful regulators of gene
expression in several organ systems of the body. The plasma
levels of these steroids are controlled through a neuroendo¬
crine feedback loop which ensures that corticosteroid levels are
optimal for homeostatic adaptation (Dallman el al., 1992).
Major sites of corticosteroid feedback action include the
3 Author for correspondence.
* A preliminary report of this work has been published in Journal of
Endocrinology 152 S PI56, 1997.
anterior pituitary gland, the hypothalamus and further sites in
the central nervous system (Sapolsky et al., 1990).
The cellular mechanisms underlying corticosteroid feedback
of the hypothalamic-pituitary-adrenocortical system are not
well understood. The anterior pituitary corticotroph has
served as a useful model to examine this problem (Antoni,
1996; Buckingham, 1996). In corticotroph cells corticosteroid
inhibition typically occurs in two main phases, designated
early (within 2 h) and late (2-24 h) (Antoni, 1996; Bucking¬
ham, 1996). Late inhibition appears to be mediated by negative
regulatory elements in DNA and leads to the suppression of
1736 M.C. Lim et al Depolarization counteracts glucocorticoid inhibition
the proopiomelanocortin (ACTH precursor) (Lundblad &
Roberts, 1988), the type 1 corticotrophin releasing-factor
(CRF) receptor (Pozzoli et al., 1996) and possibly other genes.
In contrast, the early component of inhibition is brought about
by glucocorticoid-induced protein(s), the identity of which is
unclear at present (Shipston, 1995; Antoni, 1996; Buckingham,
1996).
Recent studies in the mouse corticotroph tumour cell line
AtT20 (Shipston et al., 1996) have shown that high
conductance Ca2 + -activated K +-channels (BK-channels) play
an essential role in the inhibitory effect of dexamethasone on
CRF-induced ACTH secretion. Briefly, activation of adenylyl
cyclase by CRF produces an increase of cyclic AMP-
dependent phosphorylation and triggers Ca2+-dependent
action potentials which lead to the exocytotic release of ACTH
(see Antoni, 1993). An important element of this stimulatory
effect is the inhibition of BK-channels by cyclic AMP-
dependent protein kinase (Shipston et al., 1996). Treatment
with dexamethasone for 90 min prevented the action of CRF
and cyclic AMP analogues on BK-channels through a process
requiring the synthesis of mRNA and protein (Shipston et al.,
1996). Accordingly, the blockade of BK-channels by char-
ybdotoxin (Antoni, 1996) or iberiotoxin (Shipston et al., 1996)
obliterated the inhibitory effect of dexamethasone on
stimulated ACTH release.
The aim of the present study was to examine whether BK-
channels are also essential for corticosteroid feedback
inhibition in non-tumoural corticotroph cells. Experiments
were carried out in vitro, using AtT20 cells and primary
cultures of rat anterior pituitary cells. A cell-permeant cyclic
AMP analogue resistant to hydrolysis by cyclic nucleotide
phosphodiesterases (PDEs) was used as the stimulus in
combination with various compounds that cause membrane
depolarization. The rationale for this design was that increases
of intracellular cyclic AMP induced by agonists are strongly
suppressed by intracellular Ca2+ in both AtT20 and normal rat
corticotrophs (Antoni et al., 1995; Antoni, 1997), hence
changes of cyclic AMP metabolism induced by corticosteroids
could mask effects downstream of cyclic AMP formation.
The results clearly show that in contrast to AtT20 cells,
blockage of BK-channels fails to counteract early glucocorti¬
coid inhibition in cultures of rat anterior pituitary cells.
Importantly, however, corticosteroid inhibition in the rat
pituitary culture system was markedly reduced upon depolar¬
ization with high extracellular KC1, in which respect its
behaviour is analogous to AtT20 cells. Thus, the findings
support the notion that early inhibition by glucocorticoids




Unless otherwise indicated all reagents were from Sigma U.K.
(Poole, Dorset), and of the highest grade available. The
sources of other materials were as follows: CRF (human),
ACTH (human) synthetic charybdotoxin (Bachem U.K. Ltd.,
Saffron Walden); corticosterone (Roussell-UCLAF, Romain-
ville, France); 8-(4-chlorophenylthio)adenosine-3',5'-cyclic-
monophosphate (CPT-cAMP. BIOLOG, Bremen, Germany);
tetraethyl ammonium hydrochloride (TEA, Aldrich, Gilling-
ham, Dorset); (-)BayK8644, (RBI, Sigma, U.K.); ( +>202-791
(Novartis, U.K.); TRL-3 trypsin (Worthington, Lome
Laboratories, Reading, U.K.); Sheep anti-ACTH serum was
generously provided by Prof P.J. Lowry, University of
Reading; anti-sheep/goat IgG donkey serum was generously
provided by the Scottish Antibody Production Unit, Carluke,
Scotland.
Cell culture
Male Wistar rats (120-200 g) were caged singly with free
access to pelleted food and tap water in a light- and
temperature-controlled environment for 24 h, and sacrificed
by decapitation before 10.30 a.m. Precautions were taken to
avoid any stressful stimulation of the animals. The anterior
pituitary glands were collected and placed in a plastic Petri
dish so that the ventral surfaces of the glands contacted the
bottom of the dish. The glands were chopped twice (the second
time after 90° rotation of the specimen platform) on a hand-
operated Mcllwain tissue-chopper setting 0.5 mm and lowest
blade force. The tissue segments were incubated in Hank's
balanced salt solution without Ca2+ and Mg2+ (HBSS,
GIBCO, Life Technologies, Paisley) supplemented with 25 mM
HEPES pH 7.4, 0.15 mM CaCl2, 0.15 mM MgS04,
0.5 mg ml-1 trypsin, 0.01 fig ml-1 DNAse I (Sigma D-4527)
and 0.25% bovine serum albumin (BSA, Sigma A-7906) for
30 min at 37°C under constant shaking at 250 cycles/min, on a
IKA Vibrax orbital shaker. Following trypsinization, 200 g\ of
104 kallikrein unit/ml Trasylol® (Bayer U.K.) was added and
the tissue segments were triturated with a 1 ml Gilson pipette
tip attached to the end of a 5 ml polystyrene pipette for
10 min. The suspension was then filtered through 70 fiM nylon
mesh and centrifuged at 200 g for 10 min. The pelleted cells
were resuspended in 5 ml HBSS supplemented with 25 mM
HEPES pH 7.4, 0.15 mM CaCl2, 0.15 mM MgS04,
0.01 /rgmU' DNAse I, 0.25 mg ml-1 soybean trypsin in¬
hibitor (Sigma T-6522), recentrifuged and suspended in
Dulbecco's Modified Eagle's Medium (DMEM, containing
4.5 g glucose/L) supplemented with 2.5% foetal calf serum
(Harlan Seralab, Sussex) and 7.5% horse serum (Sigma H-
1138). Cell viability as assessed by Trypan Blue exclusion was
over 95%. Approximately 5 x 104 cells/well were plated in 24-
well plates and cultured in a humidified incubator with 5%
C02/95% air at 37°C for 4 days.
AtT20 cells were maintained in DMEM (containing 4.5 g/L
glucose) supplemented with 10% foetal calf serum as
previously described (Woods et al.. 1992). All cells used were
of passage 30 or less.
Assay of ACTH secretion
The experimental procedures for ACTH secretion were
identical for AtT20 cells and primary cultures. The cells
were first washed free of serum with 2x0.5 ml of
incubation medium (DMEM, GIBCO 31600-026, without
Na2HC03, supplemented with 25 mM HEPES pH 7.4 and
0.25% BSA (Sigma, A-4378) and incubated in this medium
at 37°C for 1 h, after which steroids and inhibitors of
mRNA or protein synthesis were introduced, and incuba¬
tion was continued for a further 2 h. Steroids were
dissolved at 10~2 M in dimethylsulphoxide and diluted with
incubation medium. Corresponding vehicle controls con¬
tained the requisite amounts of dimethylsulphoxide
throughout.
In the case of primary cultures, K+ channel blockers and
Ca2+-channel activators were added during the last 30 min of
the 2 h preincubation period because normal corticotrophs
appear to be relatively resistant to depolarization. After 2 h of
preincubation, the wells were washed once more with
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incubation medium and the secretagogues and requisite
inhibitors were added in 0.5 ml of fresh incubation medium.
In some experiments, high KC1 medium which was composed
of two parts incubation medium and one part 120 mM KC1,
1 mM MgS04, 1.8 mM CaCl2, 25 rnM HEPES 0.25% BSA,
Ca2 + -free medium (120 mM NaCl, 2.4 mM KC1, 1.2 mM
K2HP04, 1.2 mM MgS04, 4.5 g/L D-glucose, 0.2 mM EGTA,
25 mM HEPES, 0.25% BSA, Minimum Essential Medium
vitamins and amino acids) or Ca2+-free high KC1 medium (two
parts of the Ca2+-free medium mixed with one part of 120 mM
KC1, 1.2 mM MgS04, 0.2 mM EGTA, 25 mM HEPES, 0.25%
BSA, vitamins and amino acids) were used. The test incubation
period was 60 min for primary cultures and 30 min for AtT20
cells after which the tissue culture trays were placed on ice.
Any cells detached from the bottom of the wells were pelleted
by centrifugation at 200 g for 10 min at 4°C after which
aliquots of the supernatant were collected and assayed for
ACTH content by radioimmunoassay. Sheep anti ACTH
serum used in the assay was generously provided by Prof P.J.
Lowry, University of Reading and the donkey antisheep IgG
serum was obtained from the Scottish Antibody Production
Unit, Carluke, Scotland.
Analysis of results
Each experiment was carried out at least twice with n replicates
for each treatment within each experiment. All data are
presented as mean + s.e.mean and were analysed by 2- or 1-
way analysis of variance followed by Dunnett's test, Newman
Keuls' test or contrast of means where appropriate. Results
presented as percentage of control ACTH release were derived
from the raw data as follows: (X-B)/(C-B) x 100%, where B
refers to the basal ACTH secretion, C refers to ACTH
secretion elicited by the control stimulus and X refers to
ACTH secretion elicited by the control stimulus in the presence
of dexamethasone or corticosterone.
Results
Experiments with AtT20 cells
Response to CPT-cAMP and dexamethasone Concentration-
dependent stimulation of ACTH release was evoked by CPT-
cAMP (Figure 1) and the response plateaued at 1 mM CPT-
cAMP. Pretreatment with 100 nM dexamethasone significantly
reduced the increase in CPT-cAMP-stimulated ACTH secre¬
tion, basal hormone output remained unaltered (Figure 1).
Effects of depolarizing agents The ACTH response to 1 mM




Figure 1 The effect of CPT-cAMP 011 ACTH secretion by AtT20
cells pretreated for 2 h with vehicle (O) or 100 nM dexamethasone
(#). Means, the bars indicate s.e.mean, » = 5/group. Where error
bars are not visible, the s.e.mean bar is less than the space required
for the symbol. Results shown are representative of four identical
experiments.
% change of stimulated ACTH release
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Figure 2 Effect of membrane depolarizing agents, 5 pM
(—)BayK8644 (BayK) and 5 mM tetraethylammonium (TEA) on
ACTH secretion elicited by 1 mM CPT-cAMP (CPT) after 2 h
preincubation with vehicle or 100 nM dexamethasone in AtT20 cells.
Data are means, bars indicate s.e.mean, « = 4/group. (A) The empty
columns show ACTH release by vehicle treated cells and the hatched
columns show release after treatment with dexamethasone. tP<0.02
for the interaction between CPT alone and the respective depolarizing
agents alone, 2-way ANOVA. *P<0.05 when compared to
corresponding vehicle-treated release, 1-way ANOVA followed by
contrast of means. (B) data are expressed as % change in the amount
of ACTH secretion caused by dexamethasone when compared with
the respective control groups shown in A. **P<0.05 when compared
with CPT alone. 1-way-ANOVA followed by Dunnett's test. Results
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5 mM tetraethylammonium (TEA) or the Ca2+-channel
activator ( —)BayK8644 at 5 [iM (Figure 2A). Both of these
compounds stimulated ACTH release when given alone and
exhibited synergistic interaction with CPT-cAMP. Similar data
were obtained with another L-channel activator ( + )202-791
at 5 yM (not shown).
The release of ACTH evoked by 1 mM CPT-cAMP was
inhibited by 65.8 ±8.9% (n — 5) by 100 nM dexamethasone,
while basal secretion was not significantly altered (Figure 2A
and B). The inhibition of ACTH secretion stimulated by a
combination of 1 mM CPT-cAMP and 5 mM TEA or 1 mM
CPT-cAMP and 5 pM ( —)BayK8644 was significantly
attenuated to 30.7+11.8% and 31.9 + 7.6% (P<0.05, n = 5),
respectively (Figure 2A and B). The combination of 1 mM
CPT-cAMP with 5 pM ( + )202-791 also significantly reduced
the inhibition of the stimulated ACTH secretion by 100 nM
dexamethasone to 27± 1.3% (P<0.05, n = 4/group, 1-way-
ANOVA. Dunnett's test).
As both (—)BayK8644 and TEA partially reversed
dexamethasone inhibition of CPT-cAMP stimulated ACTH
secretion, the combination of these compounds with CPT-
cAMP was tested subsequently, using a submaximal concen¬
tration (0.1 mM) of CPT-cAMP as well as 1 mM CPT-cAMP.
The ACTH secretion elicited by 0.1 mM CPT-cAMP was
significantly potentiated by 5 pM (—)BayK8644 and 5 mM
TEA given together (Table 1). CPT-cAMP-induced ACTH
secretion was inhibited by dexamethasone (1 nM to 1 /(M) in a
concentration dependent manner by up to 84% (Table 1). The
combination of 5 pM (—)BayK8644 and 5 mM TEA elicited a
3-fold increase in ACTH secretion over basal levels and this
response was not inhibited by dexamethasone (Table 1). The
ACTH response elicited by the combination of 0.1 mM CPT-
cAMP, 5 pM (—)BayK8644 and 5 mM TEA was also fully
resistant to inhibition by 1-1000 nM dexamethasone (Table
1).
Similar results were obtained by combining 1 mM CPT-
cAMP with 5 mM TEA and 5 pM ( —)BayK8644. A summary
of these data (Figure 3) shows that the extent of resistance to
glucocorticoid inhibition was independent of the amplitude of
stimulus-evoked ACTH secretion. For instance, although the
ACTH response elicited by 5 mM TEA or 1 mM CPT-cAMP
alone were similar, the ACTH response to 5 mM TEA was
much more resistant to dexamethasone inhibition than the
ACTH response to 1 mM CPT-cAMP.
Taken together, these results are in agreement with previous
studies of CRF-induced ACTH release in AtT20 cells, which
have shown that early glucocorticoid inhibition is effectively
antagonized by depolarization of the membrane potential
(Woods et al., 1994) and that TEA sensitive K.+-channels,
particularly BK-type channels underlie the inhibitory action of
corticosteroids (Shipston et al., 1996).
Experiments with primary cultures of rat anterior
pituitary cells
Response to CPT-cAMP The time-course of the ACTH
response to CPT-cAMP was close to linear over 4 h (Figure
4A). The concentration-response relationship between CPT-
cAMP and ACTH release was similar at 60, 120 and 240 min,
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Figure 3 Size of the ACTH secretory response fails to predict the
degree of dexamethasone inhibition in AtT20 cells. Data were plotted
as stimulus strength vs ACTH response, where stimulus strength is
the size of the evoked release of ACTH expressed as % of the
response to 1 mM CPT-cAMP run in the same experiment, and
ACTH response is the size of the ACTH response to the respective
stimulus in cells preincubated with 100 nM dexamethasone, expressed
as percentage of the control (i.e. no dexamethasone) response. Data
are means n = 4/group. Symbols: CPT. 1 mM CPT-cAMP: BayK,
5 (—)BayK8644: TEA, 5 mM tetraethylammonium; BayK/TEA,
combination of 5 pM ( —)BayK8644 and 5 mM tetraethylammo¬
nium;-!-sign indicates that two stimuli were applied together. Results
shown are representative of two identical experiments.
Table I Characterization of the ACTH secretory response to CPT-cAMP, TEA and (—)BayK8644 in the presence of increasing












































Data show ACTH release expressed in fmol per well and represent means ±s.e.mean, of four replicates per treatment group. Values in
parentheses represent percentages of control ACTH release (mean + s.e.mean), as defined in Methods. *.P<0.02 for the interaction
between CPT and TEA/BayK in the absence of dexamethasone pretreatment, 2-way ANOVA. Statistical analysis of the effect of
dexamethasone was carried out on the data expressed as percentages (values shown in parentheses) of the respective stimulus-evoked
release, tP<0.05 when compared to the corresponding CPT group, 1-way ANOVA followed by Dunnett's test. Results shown are
representative of two identical experiments.
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stimulation of ACTH release (Figure 4B). This was not the
case at 30 min, where 1 mM CPT-cAMP was significantly
more effective than 0.1 mM CPT-cAMP. All subsequent
experiments were terminated at the 60 min time-point.
Lack of an effect of K+ -channel blockers and BayK8644 on
corticosteroid inhibition of ACTH release Corticosterone
(100 nM) reduced the ACTH response to 0.1 mM CPT-cAMP
by 74.8+10.8% (« = 5) and this was not modified in the
presence of TEA (5-20 mM) or ( — )BayK8644 (5 pM). Similar
findings were obtained with 30 nM dexamethasone. Combina¬
tion of 5 mM TEA and (—)BayK8644 (5 ^m) produced a
significant enhancement of the ACTH releasing effect of CPT-
cAMP (0.3 mM) (Basal: 34±6 fmol/well; CPT-cAMP: 125 + 5
fmol/well, P< 0.0001, n = 6; TEA + BayK: 60 ±6 fmol/well,







O 0.03 mM CPT
♦ 0.1 mM CPT










Figure 4 Effect of CPT-cAMP on ACTH secretion by primary
cultures of rat anterior pituitary cells. (A) Time-course of hormone
release in cells treated with vehicle (#), 30 pM CPT-cAMP (O),
0.1 mM CPT-cAMP (♦) or 1 mM CPT-cAMP (A). (B) Concentra¬
tion-dependent stimulation of ACTH secretion by CPT-cAMP at
30 min (A), 1 h (A), 2 h (O) and 4 h (#) of incubation. Means,
bars indicate s.e.mean, n = 4/group. Where error bars are not visible,
the s.e.mean bar is less than the space required for the symbol.
Results shown are representative of two identical experiments.
P<0.0002, n = 5; CPT-cAMP + TEA + BayK: 204+14 fmol/
well, P<0.03, interaction, » = 7, 2-way-ANOVA) but failed to
modify the inhibition by 100 nM dexamethasone (% inhibition
of CPT-cAMP w CPT-cAMP + TEA + BayK: 63 ±7% vv
66±6%, n = 4). Finally, preincubation with charybdotoxin
(30 nM) or apamin (100 nM) and the combination of these
agents with 0.1 mM CPT-cAMP also failed to modify
corticosterone inhibition of stimulated ACTH secretion (not
shown).
These data indicate that in contrast to AtT20 cells, TEA-
sensitive ion-channels are not fundamentally important for
corticosteroid inhibition of ACTH secretion in primary
cultures of rat anterior pituitary cells.
Depolarization with 40 mM KCl counteracts glucocorticoid
effect on ACTH The ACTH responses to 0.1 mM CPT-
cAMP and 40 mM KCl are shown in (Table 2). KCl (40 mM)
synergized with 0.1 mM CPT-cAMP to stimulate ACTH
release, furthermore, it produced a marked reduction in the
inhibitory effect of dexamethasone (Table 2). Omission of
Ca2+ from the incubation medium completely blocked ACTH
release induced by CPT-cAMP alone or CPT-cAMP and KCl
(not shown). Dexamethasone (10 nM) inhibited the ACTH
response to 0.1 mM CPT-cAMP and 40 mM KCl by only
44+12% (n = 4), while that evoked by 0.1 mM CPT-cAMP
was completely blocked. Similar results were also obtained
using the naturally occurring corticosteroid corticosterone
(Table 2).
The data above demonstrate that depolarization of the
membrane potential markedly reduces the early inhibitory
effect of glucocorticoids. However, the lack of a complete
block of steroid action by 40 mM KCl raises the question of
whether or not the inhibitory effect may be completely
accounted for by the rapid induction of mRNA and protein
by glucocorticoids.
Blockers ofmRNA and protein synthesis abolish glucocorticoid
inhibition The inhibition of 0.1 mM CPT-cAMP stimulated
ACTH secretion by 10 nM dexamethasone was eliminated in
the presence of 5,6-dichloro-furanosyl-benzimidazole riboside
(DRB), an adenosine analogue and inhibitor of heteronuclear
RNA synthesis (Egyhazi et al., 1982) (Figure 5A). In the
presence 40 mM KCl, DRB suppressed ACTH secretion
elicited by 0.1 mM CPT-cAMP but no further change was
observed after treatment with dexamethasone (Figure 5B).
Therefore, the residual inhibition by corticosteroids observed
in the presence of 40 mM KCl and 0.1 mM CPT-cAMP is likely
to be due to glucocorticoid blockade of this DRB sensitive
mechanism. Similar results were obtained using 0.1 mM
puromycin, an inhibitor of protein synthesis (not shown).
Discussion
The data presented here show that control of the membrane
potential is essential for glucocorticoid inhibition of stimulated
ACTH release in both AtT20 cells and primary cultures of rat
anterior pituitary cells. However, in contrast to tumoural
AtT20 cells where BK-channels are pivotal targets of
glucocorticoid action (Shipston et al., 1996), blockage of BK-
and other TEA-sensitive K ! -channels failed to modify the
inhibitory action of glucocorticoids in normal rat pituitary
cells. Thus the data conform with the general hypothesis that
glucocorticoids modulate the function of plasma membrane
ion channels to reduce cellular responses of excitable cells
(Joels & de Kloet, 1994), and indicate that glucocorticoid-
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Data show ACTH release expressed in fmol per well and represent means ±s.e.mean, of four replicates per treatment group. Values in
parentheses represent percentages of control ACTH release (mean±s.e.mean), as defined in Methods. *P<0.0001 and **P<0.004 for
the interaction between CPT-cAMP and KC1 in the absence of glucocorticoid pretreatment, 2-way ANOVA. Statistical analysis of the
effect of glucocorticoids was carried out on the data expressed as percentages (values shown in the parentheses) of the respective
stimulus-evoked release, tP<0.05 when compared to the corresponding CPT group, 1-way ANOVA followed by contrast of means.
Results shown are representative of two and three identical experiments for the corticosterone and dexamethasone dose responses
respectively.
induced proteins may regulate the function of multiple plasma
membrane ion channels.
Characteristics of the primary culture system as a model
for secretagogue-glucocorticoid interaction and the use of
CPT-cAMP
Previous studies have established that the main hallmarks of
early glucocorticoid inhibition are: (i) selectivity for stimulated
ACTH release, (ii) mediation through Type II glucocorticoid
receptors, (iii) manifestation within 2 h, and (iv) a requirement
for new mRNA and protein synthesis reviewed in (Shipston,
1995). These features have been largely retained in the AtT20
D16:16 cell line (Antoni, 1996), and also characterize the rat
anterior pituitary primary culture system (Abou-Samra et al.,
1986, and present study).
A further important property of the primary culture
system is its responsiveness to physiological concentrations of
CRF and AVP (Vale et al., 1983; Oki et al., (1990)). A
somewhat surprising feature is the low response to
depolarizing stimuli such as 40 mM KC1 and BayK8644
given alone. These stimuli have been reported as inducers of
robust ACTH release by acutely prepared pituitary cells
(Gillies & Lowry, 1978; Antoni & Dayanithi, 1990b), tissue
segments (Taylor et al., 1993) as well as AtT20 cells (Guild &
Reisine, 1987). A plausible explanation of this finding is that
the aforementioned preparations possess spontaneous elec¬
trical activity, which may be due to endogenous pacemaker
potentials (e.g. AtT20 cells), or is derived from factors
released upon tissue injury due to dissection in pituitary
segments (Taylor et al., 1993), or is a remnant of the trophic
actions of CRF in vivo (Ixart et al., 1991). Spontaneous
electrical activity will facilitate the effects of the usage-
dependent L-channel activator (—)BayK8644 (Sanguinetti &
Kass, 1984). Furthermore, the secretagogue potencies of
(—)BayK8644 as well as high KC1 are likely to depend on
tonic cyclic AMP-dependent phosphorylation which is
required for the optimal functioning of L-type Ca2+ channels
(Armstrong & Eckert, 1987) and exocytotic processes
(Morgan et al., 1993).
With respect to the requirement for cyclic AMP, it is known
that acutely dispersed cells produce much more reliable
responses to short pulses CRF if 'primed' with several pulses
of the peptide (Antoni et al., 1990b). Moreover, it has been
reported that cyclic AMP and Ca2+ synergize to trigger ACTH
release from permeabilized AtT20 cells (Guild, 1991), further
indicating that cyclic AMP-dependent processes acting in
parallel to the mobilization of Ca2+ are important for the
secretory response of corticotroph cells. It is of note that while
depolarization with 40 mM KC1 was not a reliable stimulus of
ACTH release on its own, it consistently produced a
synergistic enhancement of the CPT-cAMP induced ACTH
response. As the main result of KC1 depolarization is Ca2+
influx through voltage-operated channels (Meier et al., 1988),
the synergy of CPT-cAMP and KC1 depolarization appears
analogous to the Ca2+ potentiation of cAMP-induced ACTH
release in AtT20 cells. Similar results have been obtained using
physiological concentrations ofCRF (Lim et al., unpublished).
A cell- membrane permeant, non-metabolizable analogue of
cyclic AMP, CPT-cAMP, was used as the secretagogue
stimulus in this study in order to produce a sustained increase
in cyclic AMP-dependent phosphorylation. As the physiologi¬
cal ACTH secretagogues, CRF or CRF and AVP in
combination, activate cyclic AMP-dependent phosphorylation
in corticotrophs (see Antoni, 1993), CPT-cAMP will mimic
this aspect of agonist action. It is also clear that CRF-induced
cyclic AMP responses are subject to negative feedback
regulation by intracellular free Ca2+ at the level of adenylyl
cyclase and cyclic AMP hydrolysis in AtT20 cells (Antoni,
1996) as well as rat anterior pituitary cells (Antoni, 1997).
CPT-cAMP is largely resistant to Ca2+-feedback and this
property makes it a potentially useful tool for studying
processes of ACTH release downstream of cyclic AMP
formation. It is of note, however, that CRF elicits oscillations
of intracellular free Ca2+ in AtT20 cells as well as normal rat
corticotrophs, (see Antoni, 1993 for review), which may be
accompanied by oscillations of intracellular cyclic AMP levels
(Cooper et al., 1998). Thus, clamping the intracellular cyclic
AMP through CPT-cAMP, which leads to sustained increases
of intracellular free Ca2+ as opposed to oscillations (Mollard




















Figure 5 Effect of the RNA synthesis inhibitor 5,6-dichloro-
furanosyl-benzimidazole riboside (DRB) on ACTH secretion in
primary cultures of rat anterior pituitary cells. 100 jum DRB and
100 nM dexamethasone (DEX) were applied 2 h before challenging
the cells with (A) 0.1 mM CPT-cAMP or (B) 0.1 mM CPT-cAMP and
40 mM KC1 for 60 min. Basal ACTH release was 44+ 3 fmol/well
and was not altered by DRB or dexamethasone. Data are means,
bars indicate s.e.mean, « = 5/group. *P<0.05 when compared with
control group receiving vehicle only. 1-way-ANOVA followed by
Newman-Keuls test. Results shown are representative of four
identical experiments.
et al., 1992), may potentially alter some properties of the
ACTH response when compared with physiological agonists.
Indeed, inhibition ofmRNA or protein synthesis significantly
attenuated the release of ACTH by rat pituitary corticotrophs
to CPT-cAMP-based stimuli, whereas such manipulations
were without effect on CRF-induced ACTH secretion (Day-
anithi & Antoni, 1989; Taylor et al., 1993 and Lim et al.,
unpublished). In other respects, however, CPT-cAMP-stimu-
lated ACTH release was largely dependent on extracellular
Ca2+ and blocked by glucocorticoids similarly to ACTH
secretion evoked by CRF.
Properties of early glucocorticoid inhibition in AtT20
cells
The results with AtT20 cells extend previous work from this
laboratory examining CRF-induced ACTH release in these
cells. Overall, ACTH release induced by CPT-cAMP alone
was potently inhibited by dexamethasone. By contrast,
responses to stimuli that cause depolarization such as TEA,
(—)BayK8644 or ( + )202-791 were resistant to glucocorti¬
coid inhibition. It was also clear that the nature of the
stimulus rather than the size of the evoked response predicted
the degree of glucocorticoid inhibition in AtT20 cells. Thus,
these data are in full agreement with earlier findings from this
laboratory indicating that the principal target of corticoster¬
oid inhibition is the membrane potential (Pennington et al.,
1994; Shipston et al., 1996) rather than the secretory
apparatus as proposed by others (Castellino et al., 1992).
Further, the data are in agreement with the findings that BK-
channels (Shipston et al., 1996) are pivotal for glucocorticoid
inhibition in AtT20 cells.
Corticosterone action in primary cultures: deviation from
and convergence to AtT20 model
Importantly, the involvement of plasma membrane ion-
channels in glucocorticoid action has not been previously
addressed in normal rat corticotrophs. A report from another
laboratory has shown (Halili-Manabat et al., 1995) that
ACTH secretion stimulated by the depolarizing agent
veratridine, an opener of tetrodotoxin sensitive Na+-channels
is resistant to inhibition by dexamethasone, and our group has
reported similar findings in preliminary form using combina¬
tions of CRF and veratridine (Antoni & Woods, 1992).
However, no stimuli physiological to corticotrophs have been
identified so far that operate through Na+-channels and thus
counteract glucocorticoid feedback inhibition (Antoni, 1993;
Halili-Manabat et al., 1995).
In sharp contrast to AtT20 cells, concentrations of TEA as
high as 20 mM failed to dent significantly the early inhibitory
action of corticosterone or dexamethasone in primary cultures
of rat anterior pituitary cells. Also of note is that apamin and
charybdotoxin, blockers of SK- and BK-type Ca2+-activated
K +-channels were also without effect. In contrast to the
channel blockers tested so far, 40 mM KC1 synergized with
CPT-cAMP to stimulate the release of ACTH, while having
relatively little effect on its own. Furthermore, the early
inhibitory effects of dexamethasone as well as corticosterone
were drastically reduced with CPT-cAMP and KC1 as the
stimulus. The release of ACTH under these conditions was
fully dependent on extracellular Ca2 + , hence indicating that
the mechanism of hormone release is not fundamentally
altered by the addition of 40 mM KC1.
Overall, these findings are surprising, as channels sensitive
to the K +-channel blockers applied in the present study, and
functionally relevant for the regulation of ACTH release have
been previously reported in various preparations of cortico¬
tropin cells (Marchetti et al., 1987; Antoni & Dayanithi, 1990a).
The possibility that the K "-channel profile of corticotrophs is
altered by culture conditions cannot be discounted at present.
A recent report (Lee & Tse, 1997) suggests that CRF-induced
activation of cultured rat pituitary corticotrophs is the result of
the inhibition of a K + -current that is insensitive to TEA as well
as 4-aminopyridine. However, as noted above, the role of K +
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Table 3 Comparison of early corticosteroid inhibition of
stimulated ACTH release in AtT20 cells and primary
cultures of rat anterior pituitary cells
Common features:
Onset within 2h
Mediated by Type II glucocorticoid receptor
Requirement of new mRNA and protein
synthesis
Specific for agonist-induced release




Mediated by BK-type potassium channels
Primary cultures
Mediated by unidentified ion channel
May involve transcriptional block of protein
expression required for sustained release of
ACTH
channels in glucocorticoid feedback has not been previously
examined in non-tumoural corticotrophs.
The nature of the residual inhibitory effect of glucocorti¬
coids on KCl/CPT-cAMP stimulated ACTH release was
revealed in experiments with inhibitors of protein and mRNA
synthesis. As some reports suggested that early corticosteroid
inhibition does not require gene induction (Taylor et al., 1993)
we have re-examined this issue in the primary culture system.
Similarly to actinomycin D (Arimura et al., 1969; Portanova &
Sayers, 1974; Dayanithi et al., 1989) DRB blocked the early
corticosteroid inhibition of ACTH release, indicating a
requirement for mRNA synthesis. Moreover, DRB as well as
puromycin caused similar reductions in ACTH release induced
by 40 mM KC1/0.1 mM CPT-cAMP in the presence of 100 nM
dexamethasone, which had no additional effect in the presence
of these agents. The findings indicate that in case of relatively
high (>4 fold basal) ACTH responses elicited by CPT-cAMP-
based stimuli the ACTH secreted is derived through the
synthesis of new mRNA and protein, plausibly POMC, which
is blocked by glucocorticoids. In contrast to CPT-cAMP-based
stimuli, there was no apparent requirement for mRNA or
protein synthesis when CRF was used to stimulate ACTH
release (Abou-Samra et al., 1986; Dayanithi et al., 1989; Taylor
et al., 1993). Thus oscillating Ca2+/cAMP signals may be more
efficient in mobilizing/processing ACTH without a require¬
ment for de novo protein synthesis than CPT-cAMP which
elicits prolonged elevations of intracellular Ca2+ lacking an
oscillatory pattern (Mollard et al., 1992).
In summary (Table 3), it is intriguing that the same
physiologically relevant phenotype of early corticosteroid
inhibition is found in AtT20 cells and rat corticotrophs,
including counteraction by membrane depolarization, but the
underlying membrane-control mechanisms have strikingly
distinct pharmacology. Further studies should clarify whether
glucocorticoids are capable of inducing different families of
ion-channel subunits depending on the cell system under study
(Attardi et al., 1993; Levitan et al., 1996) or evoke the synthesis
of proteins that regulate the activity of several distinct ion
channels through generic mechanisms such as protein
phosphorylation (Wang et al., 1997). Data from our
laboratories (Shipston et al., 1996) favour the latter possibility
in the case of adenohypophysial corticotrophs.
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